Possible Etiology of Viral Encephalitis [1]
\r\n\tIn sum, the book presents a reflective analysis of the pedagogical hubs for a changing world, considering the most fundamental areas of the current contingencies in education.
",isbn:"978-1-83968-793-8",printIsbn:"978-1-83968-792-1",pdfIsbn:"978-1-83968-794-5",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"b01f9136149277b7e4cbc1e52bce78ec",bookSignature:"Dr. María Jose Hernandez-Serrano",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10229.jpg",keywords:"Teacher Digital Competences, Flipped Learning, Online Resources Design, Neuroscientific Literacy (Myths), Emotions and Learning, Multisensory Stimulation, Citizen Skills, Violence Prevention, Moral Development, Universal Design for Learning, Sensitizing on Diversity, Supportive Strategies",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"September 14th 2020",dateEndSecondStepPublish:"October 12th 2020",dateEndThirdStepPublish:"December 11th 2020",dateEndFourthStepPublish:"March 1st 2021",dateEndFifthStepPublish:"April 30th 2021",remainingDaysToSecondStep:"4 months",secondStepPassed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"Dr. Phil. Maria Jose Hernandez Serrano is a tenured lecturer in the Department of Theory and History of Education at the University of Salamanca, where she currently teaches on Teacher Education. She graduated in Social Education (2000) and Psycho-Pedagogy (2003) at the University of Salamanca. Then, she obtained her European Ph.D. in Education and Training in Virtual Environments by research with the University of Manchester, UK (2009).",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"187893",title:"Dr.",name:"María Jose",middleName:null,surname:"Hernandez-Serrano",slug:"maria-jose-hernandez-serrano",fullName:"María Jose Hernandez-Serrano",profilePictureURL:"https://mts.intechopen.com/storage/users/187893/images/system/187893.jpg",biography:"DPhil Maria Jose Hernandez Serrano is a tenured Lecturer in the Department of Theory and History of Education at the University of Salamanca (Spain), where she currently teaches on Teacher Education. She graduated in Social Education (2000) and Psycho-Pedagogy (2003) at the University of Salamanca. Then, she obtained her European Ph.D. on Education and Training in Virtual Environments by research with the University of Manchester, UK (2009). She obtained a Visiting Scholar Postdoctoral Grant (of the British Academy, UK) at the Oxford Internet Institute of the University of Oxford (2011) and was granted with a postdoctoral research (in 2021) at London Birbeck University.\n \nShe is author of more than 20 research papers, and more than 35 book chapters (H Index 10). She is interested in the study of the educational process and the analysis of cognitive and affective processes in the context of neuroeducation and neurotechnologies, along with the study of social contingencies affecting the educational institutions and requiring new skills for educators.\n\nHer publications are mainly of the educational process mediated by technologies and digital competences. Currently, her new research interests are: the transdisciplinary application of the brain-based research to the educational context and virtual environments, and the neuropedagogical implications of the technologies on the development of the brain in younger students. Also, she is interested in the promotion of creative and critical uses of digital technologies, the emerging uses of social media and transmedia, and the informal learning through technologies.\n\nShe is a member of several research Networks and Scientific Committees in international journals on Educational Technologies and Educommunication, and collaborates as a reviewer in several prestigious journals (see public profile in Publons).\n\nUntil March 2010 she was in charge of the Adult University of Salamanca, by coordinating teaching activities of more than a thousand adult students. She currently is, since 2014, the Secretary of the Department of Theory and History of Education. Since 2015 she collaborates with the Council Educational Program by training teachers and families in the translation of advances from educational neuroscience.",institutionString:"University of Salamanca",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"University of Salamanca",institutionURL:null,country:{name:"Spain"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"23",title:"Social Sciences",slug:"social-sciences"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"301331",firstName:"Mia",lastName:"Vulovic",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/301331/images/8498_n.jpg",email:"mia.v@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6942",title:"Global Social Work",subtitle:"Cutting Edge Issues and Critical Reflections",isOpenForSubmission:!1,hash:"222c8a66edfc7a4a6537af7565bcb3de",slug:"global-social-work-cutting-edge-issues-and-critical-reflections",bookSignature:"Bala Raju Nikku",coverURL:"https://cdn.intechopen.com/books/images_new/6942.jpg",editedByType:"Edited by",editors:[{id:"263576",title:"Dr.",name:"Bala",surname:"Nikku",slug:"bala-nikku",fullName:"Bala Nikku"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"41749",title:"Cerebrospinal Fluid Abnormalities in Viral Encephalitis",doi:"10.5772/54590",slug:"cerebrospinal-fluid-abnormalities-in-viral-encephalitis",body:'Encephalitis is defined as the presence of an inflammatory process of the brain in association with clinical manifestation of neurological system of the individual. In other words, onset of central nervous system (CNS) symptoms due to infections of the brain. Described pathogens reported as to be the causative agents for encephalitis, the majority of them are viral in origin, but sometimes bacteria or fungi or a postinfectious process. Inspite of the fact that molecular biology researches advance, new era of essentials elements in diagnosis commences, extensive tests are being used widely, the etiology of encephalitis remains unclear and unknown in a considerable degree of the patients [1-3].
Acute encephalitis includes a medical emergency. In most cases, the presence of focal neurological signs and mostly focal seizures will distinguish an encephalitic situation from an encephalopathic process. The diagnosis of encephalitis is suspected in a febrile patient who comes with altered conciousness and signs of cerebral dysfunction. The latters are so wise, therefore the dilemma of diagnosis starts with the beginning, and continues with the determination of the relevance of an infective agent. These agents may play a role in the neurologic manifestations of illness, but not necessarily by directly invading the CNS. Apart from this, there is a big challenge in distinguishing between infectious encephalitis and posinfectious encephalomyelitis. Vaccination programs were completed in the Western world already; therefore postinfectious or posimmunizative type encephalitis or encephalomyelitis (mainly acute disseminated encephalomyelitis [ADEM]) should be different in etiological aspect, since ADEM is mediated by an immunologic response to antigenic stimuli from infecting microorganisms or immunization. Noninfectious CNS diseases (e.g., fibroelastic tissue diseases, vasculitis, collagenous diseases, and paraneoplastic syndromes) can mimic encephalitis, or present with similar outcomes to those of encephalitis and should be account in the differential diagnosis. Herpes simplex encephalitis (HSE) is the commonest sporadic acute viral encehalitis in developed countries. The emergence of unusual forms of zoonotic encephalitis have an important public health problem all over the world. Vaccination and vector control measures are useful preventive strategies in the management of certain arboviral and zoonotic encephalitis [4].
Since the medical situation is emergent, in the approach to the patient with encephalitis, the main attempt should be carried out to build a reliable etiological diagnosis. Although, there are no definitive effective treatment – with few exceptions, no specific therapy is avaliable for most forms of viral encephalitis – in many cases, identification of a spesific agent – if possible – may be important for prognosis, potential prophylaxis, counseling of patients and family members, and public health issues [1].
Epidemiological clues that may help in directing the investigations for an etiologic diagnosis include season, geographical localization, travel history, occupational status, insect and animal contact, vaccinations, immunization of the insult. Therefore clinic approach should be carried out for etiology. Possible etiological agents of encephalitis – mainly viral – based on epidemiology and related risk factors are represented in Table 1. This table is revised from Infectious Diseases Society of America (IDAS) Guidelines 2008:
\n\t\t\t\tEpidemiology or risk factors\n\t\t\t | \n\t\t\t\n\t\t\t\tPossible infectious agent(s) for encephalitis \n\t\t\t | \n\t\t
\n\t\t\t\tAgammaglobulinemia\n\t\t\t | \n\t\t\t\n\t\t\t\tEnterovirus\n\t\t\t | \n\t\t
Age | \n\t\t|
Neonates | \n\t\t\tHerpes simplex virus (HSV) type 2, Cytomegalovirus (CMV), Rubella virus, | \n\t\t
Infant and children | \n\t\t\tEastern equine encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis virus, Influenza virus, La crosse virus | \n\t\t
Elderly persons | \n\t\t\tEastern equine encephalitis virus, St Louis encephalitis virus, West Nile virus, sporadic Creutzfeldt –Jacob disease (sCJD) | \n\t\t
Animal contacts | \n\t\t|
Bats | \n\t\t\tRabies virus, Nipah virus | \n\t\t
Birds | \n\t\t\tWest Nile virus, Eastern equine encephalitis virus, | \n\t\t
Cats | \n\t\t\tJapanese virus, | \n\t\t
Dogs | \n\t\t\tRabies virus, | \n\t\t
Horses | \n\t\t\tRabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Hendra virus | \n\t\t
Skunks | \n\t\t\tRabies virus, | \n\t\t
Swine | \n\t\t\tJapanese encephalitis virus, Nipah virus | \n\t\t
Immunocompromised persons | \n\t\t\tVaricella zoster virus (VZV), CMV, Human herpesvirus 6, West Nile virus, HIV, JC virus | \n\t\t
Unpasteurized milk | \n\t\t\tTick-born encephalitis virus, | \n\t\t
Insect contact | \n\t\t|
Mosquitoes | \n\t\t\tEastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, St Louis encephalitis virus, Murray Valley encephalitis virus, Japanese encephalitis virus, West Nile virus | \n\t\t
Ticks | \n\t\t\tTick-born encephalitis virus, Powassan virus, | \n\t\t
Occupation | \n\t\t|
Exposure to animals | \n\t\t\tRabies virus, | \n\t\t
Expoure to horse | \n\t\t\tHendra virus, | \n\t\t
Exposure to old World primates | \n\t\t\tB virus | \n\t\t
Laboratory workers | \n\t\t\tWest Nile virus, HIV, | \n\t\t
Physicians and health care workers | \n\t\t\tVZV, HIV, Influenza virus, measles virus, | \n\t\t
Veterinarians | \n\t\t\tRabies virus, | \n\t\t
Person to person transmission | \n\t\t\tHSV (neonatal), VZV, Venezuelan equine encephalitis virus (rare), Poliovirus, nonpolio Enterovirus, Measles virus, Nipah virus, Mumps virus, Rubella virus, Epstein-Barr virus (EBV), Human herpesvirus 6, B virus, West Nile virus (transfusion, transplantation, breast feeding), HIV, Rabies virus (transplantation), Influenza virus, | \n\t\t
Recent vaccination | \n\t\t\tAcute disseminated encephalomyelitis, | \n\t\t
Recreational activities | \n\t\t|
Camping/hunting | \n\t\t\tAll agents transmitted by mosquitoes and ticks (see above) | \n\t\t
Sexual contact | \n\t\t\tHIV, | \n\t\t
Spelunking | \n\t\t\tRabies virus, | \n\t\t
Swimming | \n\t\t\tEnterovirus, | \n\t\t
Seasons | \n\t\t|
Late summer/early fall | \n\t\t\tAll agents transmitted by mosquitoes and ticks (see above), Enterovirus | \n\t\t
Winter | \n\t\t\tInfluenza virus | \n\t\t
Travel | \n\t\t|
Africa | \n\t\t\tRabies virus, West Nile virus, | \n\t\t
Australia | \n\t\t\tMurray Valley encephalitis virus, Japanese encephalitis virus, Hendra virus | \n\t\t
Central America | \n\t\t\tRabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, St. Louis encephalitis virus, | \n\t\t
Europe | \n\t\t\tWest Nile virus, Tick-born encephalitis virus, | \n\t\t
India, Nepal | \n\t\t\tRabies virus, Japanese encephalitis virus, | \n\t\t
Middle East | \n\t\t\tWest Nile virus | \n\t\t
Russia | \n\t\t\tTick-born encephalitis virus, | \n\t\t
South America | \n\t\t\tRabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, St Louis encephalitis virus, | \n\t\t
Southeast Asia, China, Pasific Rim | \n\t\t\tJapanese encephalitis virus, Tick-born encephalitis virus, Nipah virus | \n\t\t
Unvaccinated status | \n\t\t\tVZV, Japanese encephalitis virus, Poliovirus, Measles virus, Mumps virus, Rubella virus | \n\t\t
Possible Etiology of Viral Encephalitis [1]
Clinical findings (physical and specific neurological signs and symptoms) may indicate certain causative agents in patients with encephalitis (Table 2). This table is again revisely taken from the same guideline mentioned in the previous paragraph [1];
\n\t\t\t\tClinical presentation\n\t\t\t | \n\t\t\t\n\t\t\t\tPossible infectious agent\n\t\t\t | \n\t\t
General findings | \n\t\t|
Lymphadenopathy | \n\t\t\tHIV, EBV, CMV, Measles virus, Rubella virus, West Nile virus, | \n\t\t
Parotitis | \n\t\t\tMumps virus | \n\t\t
Rash | \n\t\t\tVZV, B virus, Human herpesvirus 6, West Nile virus, Rubella virus, certain Enteroviruses, | \n\t\t
Respiratory tract findings | \n\t\t\tVenezuela equine encephalitis virus, Nipah virus, Hendra virus, Influenza virus, Adenovirus, | \n\t\t
Retinitis Urinary symptoms | \n\t\t\tCMV, West Nile virus, St Louis encephalitis virus (early) | \n\t\t
Neurological findings | \n\t\t|
Cerebellar ataxia | \n\t\t\tVZV (in children), EPV, Mumps virus, St. Louis encephalitis virus, | \n\t\t
Cranial nerve abnormalities | \n\t\t\tHSV, EBV, | \n\t\t
Dementia | \n\t\t\tHIV, Human transmissible spongiform encephalopathies, sCJD and variant Creutzfeldt-Jacob disease (vCJD), Measles virus (Subacute sclerosing panencephalitis (SSPE)) | \n\t\t
Parkinsonism | \n\t\t\tJapanese encephalitis virus, St. Louis encephalitis virus, West Nile virus, Nipah virus, | \n\t\t
Poliomyelitis-like flaccid paralysis | \n\t\t\tJapanese encephalitis virus, West Nile virus, Tick-born encephalitis virus, Enterovirus (enterovirus-71, coxsackieviruses), Poliovirus | \n\t\t
Rhombencephalitis | \n\t\t\tHSV, West Nile virus, Enterovirus 71 | \n\t\t
Possible etiological agents of viral Encephalitis based on clinical findings
Cerebrospinal fluid (CSF) is produced in choroid plexus of brain ventricules and in subarachnoid pial surface. Noninfective CSF contains maximum 5 wight blood cells (WBC) in a mm3. The protein content in normal CSF does not exceed 50mg/dl and CSF glucose is 50-70 % of serum glucose levels. Central nervous system infections alter this normal content in varied degrees. Thus, knowing these alerations in various infectious and noninfectious situations is crucial for attaining veritable diagnosis. CNS infections should be born in mind in patients, who attain to emergency departments with fever, impaired consciousness and findings attributed to nervous system. Obtaining CSF with lumber puncture performed in early period leads to at once, differentiation of central pathologies from systemic ones, of infectious etiologies from noninfectious causes, and getting data concerning the character of a possible central nervous system infection; therefore CSF analysis maintains its importance as a valid method currently, for searching brain infections.
Lumbar puncture is performed generally from L4-5 intervertebral space. However L3-4 and L5-S1 intervertebral spaces are also utilized. Sufficient CSF sample should be obtained for routine laboratory tests, and a certain amount should be spared for advanced tests. Initially, protein and glucose levels are analysed from obtained sample, white blood cell count is done, and cultural analyses are performed. Opening pressure and protein concentration are increased, and glucose levels are decreased in bacterial menengitis. Polymorphonuclear cells (PNL) are usually found. Opening pressure is normal or mildly increased however in viral encephalitis and menengitis. In a classical viral encephalitis glucose levels are normal, but protein concentration is found to be mildly or moderatly increased. CSF findings in several infectious situations is summarized in Table 3.
\n\t\t\t | \n\t\t\t\tBacterial menengitis\n\t\t\t | \n\t\t\t\n\t\t\t\tViral encephalitis\n\t\t\t | \n\t\t\t\n\t\t\t\tFungal menengitis\n\t\t\t | \n\t\t\t\n\t\t\t\tTuberculose menengitis\n\t\t\t | \n\t\t
\n\t\t\t\tPressure\n\t\t\t | \n\t\t\tIncreased | \n\t\t\tNormal-mildly increased | \n\t\t\tNormal-mildly increased | \n\t\t\tIncreased | \n\t\t
\n\t\t\t\tGlucose\n\t\t\t | \n\t\t\tLow | \n\t\t\tNormal | \n\t\t\tLow | \n\t\t\tLow | \n\t\t
\n\t\t\t\tCell count\n\t\t\t | \n\t\t\tPNL | \n\t\t\tMononuclear | \n\t\t\tMononuclear | \n\t\t\tPNL/mononuclear | \n\t\t
\n\t\t\t\tProtein\n\t\t\t | \n\t\t\tHigh | \n\t\t\tHigh | \n\t\t\tHigh | \n\t\t\tHigh | \n\t\t
General characteristics of various CNS infections
In viral encephalitis, a more important problem is to find out the etiological agent and to apply therefore the appropriate antiviral agent beginning from the early period of the disease. Nevertheless, CSF findings, as they are analysed by routine tests, are not specific in viral encephalitis, and couldn’t be heplfull to distinguish different etiological agents. These findings combined with radiological data could also not be assistant, and determination of etiology may be delayed. As a matter of fact, various serological methods, cell cultures and genom analyses are widely utilised currently. Methods to apply should be adapted to geographical factors, to epidemyological data, and to travel history in a specific individual. Negative results does not always rule out a certain agent, therefore repeated tests could be needed.
A hemorhagic CSF could be seen in Herpes simplex type I encephalitis [5]. Lymphositic pleocytosis (10-500 mononuclear cell/mm3) and increased protein concentrations are usually found [6]. However, in immuncompromised patients especially, one could not encounter typical pleocytosis. Thus, CSF findings could be misleading in such situations; before ruling out the disease or an etiological agent, a wider CSF screen is needed in these patients. Determination of HSV-DNA with polymerase chain reaction (PCR) is a widely utilised method today. As a gold diagnostic standart currently, PCR’s sensitivity is 95 % in Herpes simplex type I, and its specifity is 100 % [7]. Since the identification of HSV-I in the early period of the disease is an ongoing problem, the test should be repeated after 3-7 days in cases with negative results [1]. Studies searching for the association between HSV-DNA load and disease prognosis haven’t revealed consistent results hitherto; hence, further studies are needed [8]. Isolation of the virus in cell culture is also possible, but methods sensitivity is quite low and is not invoked in clinical practice widely. Another method is to determine specific antibodies. Blood/CSF antibody ratio below 20/1 exposes the intratecal synthesis and is usefull in diagnosis of Herpes simplex encephalitis in a considerable degree. Positive PCR results are tend to diminish with the parenteral application of acyclovir, possibility of a positive test after second week is quite decreased; in contrast, in this period of the disease, specific antibodies are easily determined. The fact that patients with negative PCR and positive oligoclonal bands are frequently encountered in a specific period of the disease suggests that these two methods are sensitive to different stages of the diseases [9]. Recent studies displayed some inflamatory cytokine level alterations in CSF. While in the early period of the disease the IFN-γ and IL-6 levels are high, at the period of 2-6 weeks, TNF-α, IL-2 and soluable CD8 levels are found to be increased [10]. Maybe, these findings are reflecting the neuronal damage and inflamatory reaction, however the clinical importance of them are not well established currently.
A lymphocytic pleocytosis is seen in Varicella zoster virus (VZV) encephalitis (below 100 cells/mm3), and increased protein concentrations and normal glucose levels are found. Opening pressure maybe increased [6]. In cell culture, the virus is rarely isolated. VZV-PCR is a usefull technique for determining the agent. Once again, negative results do not rule out the virus. In many cases, virus DNA is diminished in CSF after the first week, hence the way to be chosen is to analyze intrathecal antibodies at this period. Determining the ratio of IgG antibodies to blood content or IgM levels are helpfull. VZV glycoprotein E does not express antigenic resemblance with the herpes simplex virus, and is easily determined with performing ELISA. This method has a high specifity and sensitivity for VZV encephalitis, it may also be utilised for the differential diagnosis with herpes virus [11]. The test to be choosen in Ebstein-Barr virus and in Citomegalovirus encephalitis is again PCR. Negative results do not exclude the agents. Determining the alterations of IgM and IgG levels with serological analyses maybe usefull in EBV encephalitis. HHV-6 and HHV-7 PCR tests should be added to routine CSF screen in immuncompromised patients [5]. It should also be noted that HHV-6 PCR does not distinguish latent infection from active encephalitis. Diagnostic methods for encephalitis caused by herpesviridea family is shown in Table 4.
Besides HSV and VZV, PCR test is trusty also in JC virus. In immuncompromised patients in whom multifocal leucoencephalopathy is suspected, PCR technique is highly specific. Pleocytosis is charactheristic in Mumps encephalitis. Interestingly however, protein levels are generally normal and glucose concentrations are decreased. The disease should be differentiated from Lymphocytic choriomenengit virus, since decreased glucose levels are resulted also from that agent caused encephalitis (Figure 1). Cell culture and PCR are equally helpfull. Specific antibodies should be investigated if PCR is negative. Four fold increase in IgG levels or determining IgM are helpfull, but it should be born in mind that Mumps specific antibodies may express cross-reaction with Parainfluenza virus antibodies [6]. In the course of encephalitis caused by Enteroviruses, CSF cell count is generally normal, or a mildly mononuclear pleocytosis is present. Glucose levels are normal and protein concentration is increased. Method to be choosen is RT-PCR. Sensitivity and specifity are 86 % and 100 % respectively. Cell culture may also be helpfull. Despite Influenza encephalitis is rarely reported, it should be investigated in pandemic situations and/or in conditions, in which no other etiological agent is determined. Routine CSF screen is usually normal. The etiological analysis is performed by RT-PCR and cell culture in suspected cases.
HSV-1 | \n\t\t\tPCR, quantitative PCR, routine serology | \n\t\t
HSV-2 | \n\t\t\tPCR, routine serology, culture | \n\t\t
EBV | \n\t\t\tPCR, routine serology | \n\t\t
CMV | \n\t\t\tPCR | \n\t\t
HHV-6, HHV-7 | \n\t\t\tPCR, routine serology, culture | \n\t\t
VZV | \n\t\t\tPCR, routine serology, VZV Ge | \n\t\t
Diagnostic methods in herpesviridae family.
CNS infections, in which low CSF glucose levels are found.
In encephalitis caused by Flaviviruses, clinical suspicion maintains its importance. Methods that target Flaviviruses should be added to routine CSF analyses in endemic regions, or in patients who have a travel history; at times, repeated lumbar punctures are needed for determining the etiological agent. In West nile virus encephalitis, domination of polymorphonuclear leukocytes in hyperacute period, leaves its place to lympocytes afterwards. CSF protein concentrations are usually increased, glucose levels are normal. RT-PCR is assistant, but it is not possible in late stages of the disease to capture the virus RNA [12]. Virus isolation by means of CSF cultures is also utilised [13]. Today the most valid methods are serological approaches. The success of ELISA in detecting WNV-specific antibodies is increased in 8-21 days after the beginning of clinical symptoms. Similar serological methods can be used in other Flavivirus infections. In Japan encephalitis, for example, the valid method currently is ELISA capture of JE-IgM [14] (Table 5). Various biomarkers, which are detected in CSF in the course of WNV encephalitis may reflect the severity of disease and neuronal damage. In 58 % of cases with WNV, NfH-SM135 and GFAP-SM126 can be found positive, S100B positivity is seen in 90 % of this same group [15]. In Eastern equine encephalitis, leucocyte count is much more increased, and it can reach 1000-2000 cells per mm3; it should also be noted that dominant cells are polymorphnuclear. CSF findings emerged from various encephalitic situations are summarized in Table 6.
As we mentioned above, a part of recent studies targets on inflammatory responses in CSF. Without question, these biomarkers are not etiology specific. However, they can be used for manifesting the severity of neuroinvasif disease. One of those markers is macrophage migration inhibitory factor (MIF) that increases in CSF in CNS infections [16]. Studies that investigate the association of these factors with possible etiological agents and disease severity is needed (Figure 2).
Several biomarkers elevating in CSF during the course of central nervous system infections.
\n\t\t\t\tFLAVIVIRUS INFECTIONS\n\t\t\t | \n\t\t
Elevated protein, high cell count (initially neutrophilic; mononuclear pleocytosis after a certain time), normal glucose concentrations | \n\t\t
RT-PCR, IgM ELISA capture | \n\t\t
Virus isolation | \n\t\t
CSF characteristics and diagnostic methods in flavivirus encephalitides
CSF findings in all types of encephalitis may expose time dependent alterations. In cases with negative PCR, repeated lumbar punctures should be performed, differences in cell count should be observed, PCR studies should be repeated and new cell cultures should be made for virus isolation. This aproach is valid in patients receiving amprical antiviral treatment also. For example, it is known that PCR becomes positive several days after the onset of clinical symptoms in herpes encephalitis. PCR test becomes negative after a certain time in HSV and VZV encephalitis. This duration is shorter in patients receiving antiviral therapy. Once again, in herpes encephalitis, intrathecal antibody production commences beginning from the second week. In West Nile virus encephalitis, initial neutrophylic dominance gives way to a lymphocytic pleocytosis. Capturing specific IgM antibodies in the first week after syptom onset leads frequently to negative results. But the chance of detection increases in the following days. Therefore it is crucial to repeat lumbar puncture in such cases. On the other hand, WNV RT-PCR is positive in a narrow period, but the possibility of a positive result decreases as the disease progresses (Table 7).
\n\t\t\t | \n\t\t\t\tcell count\n\t\t\t | \n\t\t\t\n\t\t\t\tProtein\n\t\t\t | \n\t\t\t\n\t\t\t\tGlucose\n\t\t\t | \n\t\t
\n\t\t\t\tHSV\n\t\t\t | \n\t\t\tMN | \n\t\t\tHigh | \n\t\t\tNormal-Low | \n\t\t
\n\t\t\t\tVZV\n\t\t\t | \n\t\t\tMN | \n\t\t\tHigh | \n\t\t\tNormal-Low | \n\t\t
\n\t\t\t\tCMV\n\t\t\t | \n\t\t\tMN | \n\t\t\tHigh | \n\t\t\tNormal | \n\t\t
\n\t\t\t\tMUMPS\n\t\t\t | \n\t\t\tMN | \n\t\t\tNormal- High | \n\t\t\tNormal-Low | \n\t\t
\n\t\t\t\tEnteroviruses\n\t\t\t | \n\t\t\tNormal-MN | \n\t\t\tHigh | \n\t\t\tNormal | \n\t\t
\n\t\t\t\tWNV\n\t\t\t | \n\t\t\tPNL-MN | \n\t\t\tHigh | \n\t\t\tNormal | \n\t\t
\n\t\t\t\tInfluenza\n\t\t\t | \n\t\t\tNormal | \n\t\t\tNormal | \n\t\t\tNormal | \n\t\t
\n\t\t\t\tJC virus\n\t\t\t | \n\t\t\tNormal | \n\t\t\tHigh | \n\t\t\tNormal | \n\t\t
CSF characteristics of encephalitis in various viruses.
\n\t\t\t | \n\t\t\t\tCell count\n\t\t\t | \n\t\t\t\n\t\t\t\tPCR\n\t\t\t | \n\t\t\t\n\t\t\t\tAntibody production\n\t\t\t | \n\t\t
\n\t\t\t\tHSV< 3 days | \n\t\t\tNormal-mononuclear | \n\t\t\tNegative | \n\t\t\tNegative | \n\t\t
3-14 days | \n\t\t\tMononuclear | \n\t\t\tPositive | \n\t\t\t\n\t\t\t\tNegative-Positive | \n\t\t
"/>14 days | \n\tMononuclear | \n\t\n\t\tNegative-Positive | \n\t\n\t\tPositive-Negative | \n
\n\t\tWNV <2 days | \n\tPolymorphnuclear | \n\tPositive | \n\tNegative | \n
2-7 days | \n\tMononuclear | \n\tPositive-Negative | \n\tNegative | \n
"/>7 days | \nMononuclear | \nNegative | \nPositive | \n
Time dependent alterations of CSF findings in Herpes and WNV.
Current diagnostic methods which have been described above have been providing valuable proves for diagnostic process of the viral encephalitis but new approaches are needed with increased knowledge of pathogenesis of viral encephalitis. These are must be combined according to clinical picture and possible etiological agents. These promising methods are;
Detection of viral genomic materials
RT-PCR, IgM ELISA capture
Detection of viruses
Differentiation of lytic and lstent viral infectivity
Evaluation of inflammatory markers
IFN-γ, TNF-α, IL-2, IL-6, CD8
Macrophage migration inhibitory factor (MIF)
Determination of the antibodies
Evaluation of tissue and neuronal damage products
NfH-SM135, GFAP-SM126
S100B
Related to future prospects of diagnostic methods which will evaluate biomarkers in CSF must be improved as diagnostic and also prognostic methods.
Transplant recipients constitute a group of patients who are immunocompromised. Among them, hematopoietic stem cell transplant (HSCT) recipients suffer from the most severe immunosuppression, which may be prolonged. Many risk factors make these patients prone to fungal infections caused by yeast-like fungi or molds.
Filamentous fungi of the genus Aspergillus may cause many clinical forms of the disease in immunocompromised patients (including HSCT recipients and solid organ transplant recipients), but increasingly also in patients undergoing intensive care or even without any immune deficiencies [1]. Aspergillosis usually results from inhalation of spores, affecting primarily the respiratory system [1, 2, 3]. Humans are exposed daily to massive numbers of fungal spores; however, usually they are eliminated by various pulmonary defense mechanisms, for example, mucociliary function [1, 2]. With progress in molecular diagnostic methods, particularly next-generation sequencing (NGS) techniques, we have learned that molds and yeast-like fungi are present in the respiratory tract, even in healthy individuals [4]. Similar to microbiota composition in other parts of the body, the lung mycobiota also comprises numerous fungal species, which become less diverse in many diseases [4].
Aspergillosis may present in different forms, such as invasive aspergillosis (IA), allergic aspergillosis, chronic pulmonary aspergillosis, and as superficial disease in various anatomical locations (keratitis, otomycosis, and wound infections) [1, 4, 5, 6]. Allergic aspergillosis may present as allergic bronchopulmonary aspergillosis (ABPA) and allergic fungal rhinosinusitis (AFRS) [7].
Invasive aspergillosis is further divided into invasive pulmonary aspergillosis (IPA), sinusitis caused by Aspergillus spp., disseminated aspergillosis, and several types of invasive aspergillosis with the involvement of single organs [5, 6]. In transplant recipients and other immunocompromised patients, the most common clinical form of aspergillosis is invasive pulmonary aspergillosis, which untreated or unsuccessfully treated can lead to systemic dissemination to other organs and systems, for example, brain, heart, or the bones [1, 2]. In contrast, paranasal sinuses, larynx, eyes, ears, and the oral cavity are often involved in primary aspergillosis [2].
Invasive aspergillosis is the most common mold infection, particularly among immunocompromised patients. Patients subjected to allogeneic hematopoietic stem cell transplantation (alloHSCT) constitute a group of patients with the highest risk of systemic fungal infections, caused by both Candida spp., as well as Aspergillus spp. [5, 6]. Factors predisposing to the invasive aspergillosis are prolonged neutropenia (<500/μl for >10 days) and lymphopenia (mainly affecting CD4+ cells) [5, 8, 9, 10, 11, 12]. Frequency of invasive infections caused by Aspergillus spp. is on the increase in patients undergoing chemo- and/or radiotherapy, treated with corticosteroids or immunosuppressive agents, as well as in patients with acquired immune deficiency syndrome (AIDS) or congenital deficiencies of the immune system, such as chronic granulomatous disease [1, 8, 10, 12, 13, 14]. Patients at the extremes of age (>60 and neonates), persons with chronic malnutrition, and individuals on total parenteral nutrition have fungal infections more often than patients in other groups [8, 10, 13]. Surgical procedures, particularly thoracic or abdominal surgery and solid organ transplantation, and the use of central venous catheters or dialysis catheters are linked to endogenous and exogenous infections, including those caused by Aspergillus spp. [1, 5, 6, 8, 9, 10, 11]. Underlying diseases, such as diabetes, kidney, and/or liver failure, and chronic obstructive pulmonary disease (COPD) also predispose to invasive fungal infections [1, 8].
Aspergillosis is caused by opportunistic molds of the genus Aspergillus, which contains more than 300 species; however, only relatively few of them are known to cause human diseases [12]. These fungi are ubiquitous in soil, plants, and decaying organic debris, as well as in household dust and building materials [1]. Hospitalized immunocompromised patients are at risk of aspergillosis during construction or renovation works at the hospital. Fungi Aspergillus spp. (like other molds), produce conidia that are easily aerosolized [12]. Inhaled conidia colonize the respiratory system of the host in whom—depending on the degree of immunosuppression—various clinical forms of aspergillosis may develop. Rarely, aspergillosis results from ingestion of the spores or their direct inoculation into the wounds [12].
The most common etiological agent of invasive aspergillosis with a high morality is A. fumigatus, responsible for the majority (up to 90%) of cases in humans [1, 12, 15, 16, 17, 18, 19]. It is followed by A. flavus, which causes up to 10% of cases of bronchoalveolar aspergillosis [18]. This species also is responsible for most cases of aspergillosis with sinus and skin involvement [1]. It appears that A. flavus survives better than other Aspergillus spp. in a dry and hot climate; therefore, it is mainly isolated in Asia, Middle East, and Africa [17]. Other species of the genus Aspergillus, such as A. niger, A. nidulans, A. terreus, A. versicolor, A. calidoustus, and A. ustus cause invasive infections less frequently; however, they are of importance in immunocompromised patients [12, 18, 20, 21]. Strains of A. niger colonize the respiratory tract and are etiological agents of most cases of external otitis [1]. According to the Prospective Antifungal Therapy Alliance® (PATH Alliance ®) registry, in a cohort study of 960 cases of proven/probable IA, A. fumigatus (72.6%) was the most predominant species, followed by A. flavus (9.9%), A. niger (8.7%), and A. terreus (4.3%) [12]. Recently, an increasing frequency of infections caused by environmental species of Aspergillus (of unknown significance in medicine) is being reported [21].
Apart from Aspergillus species other than A. fumigatus, recently attention is being focused on the strains classified in the section Fumigati (A. fumigatus complex), for example, Neosartorya udagawae (A. udagawae) [18, 22]. They may cause similar diseases as A. fumigatus sensu stricto; however, duration of illness may be prolonged (even sevenfold) [22]. It appears that actual prevalence of these cases may be underestimated, as these strains are often misidentified because they cannot be distinguished from A. fumigatus sensu stricto by conventional morphological tests [18]. Moreover, the outcome of treatment of these infections may be unfavorable, as strains belonging to A. fumigatus-related species (the section Fumigati) often show some level of intrinsic resistance to azoles and other antifungal drugs, with the minimum inhibitory concentrations (MICs) of various antifungals for these isolates higher than those for A. fumigatus, which is usually susceptible to azoles [22]. However, in a recent multicenter prospective study, the rate of azole resistance among A. fumigatus isolates was relatively high—3.2%, out of which 78% were A. fumigatus sensu stricto with a mutation of the cyp51A gene, while the remaining 22% were the related species (A. lentulus, A. thermomutatus, and A. udagawae) [23].
In clinical practice A. lentulus, A. udagawae, A. viridinutans, and A. thermomutatus (Neosartorya pseudofischeri), A. novofumigatus and A. hiratsukae have been linked etiologically to such refractory cases of IA [18]. These A. fumigatus complex strains are characterized by lower virulence ascribed to a lower thermotolerance and different profiles of secondary metabolites with decreased production of mycotoxins, such as gliotoxin [18]. Definitive identification of these cryptic species requires specific sequencing analyses of the beta-tubulin or calmodulin genes, which are not readily available. Clinical microbiologists should, therefore, be aware of such cryptic species of Aspergillus and the methods of their differentiation from A. fumigatus—defect in sporulation, unusual susceptibility profile to antifungals, as well as multiplex PCR assays and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) technique [18].
Molds of the genus Aspergillus may cause a wide variety of clinical entities, ranging from asymptomatic colonization, allergic bronchopulmonary aspergillosis, and chronic pulmonary aspergillosis to severe (even fulminant) invasive infections in almost every organ or system in the body of the host, including (but not limited to) the lungs, heart, central nervous system, and the sinuses [5, 18, 19, 24]. The most common clinical form of invasive diseases caused by Aspergillus spp. is pulmonary aspergillosis, which in about 50% of cases spreads to other anatomical locations, including the brain, liver, kidneys, endocardium, bones, and gastrointestinal tract [8, 10, 13, 19, 25]. Aspergillosis may also affect the paranasal sinuses, the ear, or the eyeball [13].
The spectrum of aspergillosis is determined by the host’s immune status (particularly severe and prolonged neutropenia) and the virulence of Aspergillus strain causing the infection [5, 6, 12, 13]. In immunocompetent persons, molds of the genus Aspergillus mainly cause allergic symptoms and chronic pulmonary aspergillosis, without invasion and destruction of the host’s tissues [12]. In the chronic pulmonary aspergillosis, usually a preexisting pulmonary condition is observed, such as preformed cavity in the lung (resulting from tuberculosis, sarcoidosis, or other necrotising process), in which an aspergilloma (or a fungus ball) is being formed (chronic cavitary pulmonary aspergillosis) [12]. Allergic bronchopulmonary aspergillosis (ABPA) is a disease that arises from a hypersensitivity reaction to Aspergillus antigens and most often develops in patients who have asthma, atopy, or cystic fibrosis [8, 12, 26]. Another form of aspergillosis, characterized by a local invasion of the lung parenchyma; however, without invasion or dissemination to other organs, is called subacute invasive aspergillosis (or chronic necrotizing pulmonary aspergillosis) [12].
Invasive aspergillosis is a life-threatening infection and a major cause of death in immunocompromised patients, particularly hematopoietic stem cell transplant recipients, but may be fatal even in immunocompetent individuals, with the death rate of 40% for pulmonary disease, 90% for disseminated disease, and practically 100% for disseminated disease with the central nervous system (CNS) involvement [1, 19]. According to the literature, invasive aspergillosis occurs in 1–15% of the solid organ transplant recipients, in whom mortality rates due to this disease range from 65 to 92% [1]. However, currently these indices improve in these patients due to advances in immunosuppressive regimens and transplantation practices, as well as frequent use of antifungal prophylaxis.
Recent reports indicate that invasive aspergillosis is being increasingly diagnosed in patients without above-mentioned severe neutropenia—particularly in the lung transplant recipients, patients hospitalized in the intensive care unit or treated with corticosteroids [9, 11, 27]. Also, individuals with chronic obstructive pulmonary disease (COPD), liver failure, and other underlying diseases are listed in this group [8, 11, 20]. It has been reported that in ICU patients with invasive pulmonary aspergillosis 40–80% of them do not have any malignancy or other classical risk factors for this infection [8, 20]. Moreover, in contrast to patients with neutropenia, in ICU patients the symptoms of aspergillosis are atypical; therefore the diagnosis of this infection may be delayed or omitted, according to the autopsy studies [11, 15, 28]. Tejerina et al. showed that among 893 deceased patients, previously treated in ICU, only 40% (10 out of 25) had invasive aspergillosis diagnosed ante mortem [11]. Problems with proper diagnosis of invasive asergillosis, and therefore a delay in administration of effective antifungal therapy, are undoubtfully linked to a high mortality rate in this group of patients (30–40%), which may even exceed 90% despite lack of severe immunosuppression in these individuals [15, 27, 29].
As mentioned earlier, aspergillosis affects mainly the lungs; however it may also be diagnosed in the upper respiratory tract and the oral cavity [2, 30]. Orofacial aspergillosis is relatively common in oncohematological patients undergoing chemotherapy [2].
Aspergillosis of the larynx is very rare, with only a few cases reported in the literature [31]. Usually, it is secondary form of this disease, while primary aspergillosis of the larynx is even rarer. Risk factors for aspergillosis of the larynx comprise the use of inhaled or systemic steroids, prolonged antibiotic therapy, and underlying immunosuppression [31]. It should be emphasized that these lesions may mimic malignancy or a premalignant condition, while proper diagnosis and administration of antifungal therapy, as well as elimination of the risk factors (if possible), are effective in the elimination of this condition [31].
It also appears that chronic tonsillitis may be caused by Aspergillus spp. In a study of 75 symptomatic children who underwent a tonsillectomy, in 9 (12%) of them Aspergillus was detected on histological examination of the removed tonsils [30].
Aspergillus spores may be deposited in the oral cavity upon inhalation or during dental procedures, for example, tooth extraction [3]. The fungus may then spread further into the sinuses as odontogenic infection [32, 33]. The infection may also become established in the oral cavity itself.
In oral aspergillosis, the lesions are usually located on the palate or posterior tongue [2]. They are yellow or black, with a necrotic ulcerated base. The hyphal elements of Aspergillus fungus may invade the oral mucosa through the release of various toxins, such as proteases, phospholipases, hemolysins, gliotoxin, aflatoxin, phthioic acid, and many others. Subsequently, they penetrate the blood vessels, producing thrombosis, infarction and necrosis, and then systemic spread follows [2].
Paranasal sinuses may be colonized or infected by fungi, while infection can be invasive (acute or chronic) or noninvasive (allergic sinusitis and aspergilloma) [18]. In invasive aspergillosis of the sinuses, there are rapid (within a few days) destructions of the sinuses, the nasal cavity, and the adjacent structures, such as the orbit and the brain [18]. Aspergillus spp. may also cause allergic Aspergillus sinusitis (AAS), which results from a hypersensitivity reaction to the presence of the fungus in the sinus [26]. The hallmark of AAS is demonstration of fungal elements in the material obtained from the sinus [26].
It is estimated, that fungal sinusitis constitutes 6–9% of all cases of rhinosinusitis. Among fungi causing sinusitis, the most common is Aspergillus spp. [18]. Aspergillosis of the paranasal sinus should be suspected in patients with refractory or recurrent sinusitis. Apart from the sinuses, aspergillosis may also affect the nasal cavity, from which the infection can spread to the CNS (rhinocerebral aspergillosis).
The maxillary sinus is more often affected than other paranasal sinuses. However, it is frequently misdiagnosed, even as malignancy [3, 18, 34]. Untreated infection may spread to the other structures in the head [35]. Invasive aspergillosis of the maxillary sinus should be considered in patients with maxillary sinusitis which does not respond to standard therapy with antibiotics, even in immunocompetent patients [3].
From the paranasal sinuses, Aspergillus infection may spread locally into the vasculature and the brain, leading to cavernous sinus thrombosis and a variety of central nervous system manifestations and to other locations, for example, the orbit [36]. In these cases, computed tomography (CT) or magnetic resonance imaging (MRI) and biopsy of any lesion located in the sinuses or the nasal cavity in high-risk patients is mandatory [19]. Intracranial and intraorbital extension decreases the survival rate of these patients [3].
Factors which predispose immunocompetent individuals to fungal infections in the sinuses include polyps and blocked drainage of secretions [3]. Additional risk factors for fungal sinusitis, including Aspergillus, are reported in immunocompromised patients and individuals with various underlying diseases, such as neutropenia, immunosuppressive therapy, corticosteroids, uncontrolled diabetes mellitus, trauma, burns, and radiation therapy [3]. In these patients, particularly with hematological malignancies and in transplant recipients, Aspergillus may cause an invasive infection as aggressive in its clinical course as those caused by Zygomycetes [19]. Invasive fungal sinusitis is potentially fatal, with an extremely high mortality rate, particularly in immunocompromised patients [3]. Therefore invasive aspergillosis of the paranasal sinuses has to be recognized and treated to avoid significant mortality in immunocompromised patients, particularly in transplant recipients [3]. It should be suspected in cases of purulent rhinosinusitis not responding to repeated courses of antibiotics, and on the basis of radiological features.
Therapy of fungal sinusitis depends on its clinical form. In cases of Aspergillus fungal ball of the paranasal sinuses, surgical removal alone can be sufficient [5, 6]. Enlargement of the sinus opening may be needed to improve drainage and prevent further recurrence of sinusitis [5, 6]. In invasive aspergillosis apart from surgery, also systemic antifugal therapy is recommended.
Within the lower respiratory tract, Aspergillus infection may affect the larynx, trachea, and bronchi (tracheobronchitis), as well as lung parenchyma (pulmonary aspergillosis). In rare cases, Aspergillus pleuritis has been reported [19].
The lungs are affected in up to 92% of all cases of invasive aspergillosis [19]. Invasive pulmonary aspergillosis is a clinical entity characterized by invasion of the fungal hyphae into the blood vessels (angioinvasion), which subsequent hemoptysis. Other symptoms comprise nonproductive cough, pleuritic pain, low-grade fever, and dyspnea [19]. However, in the early stages of the disease, both clinical symptoms and radiological findings may be nonspecific, so proper diagnosis and treatment may be delayed, resulting in increased mortality in this group of patients.
The frequency of invasive pulmonary aspergillosis has significantly increased in recent years due to a growing number of immunocompromised patients [8, 37]. This clinical entity most often occurs in patients with different forms of immunosuppression, for example, hematological malignancies, profound and prolonged neutropenia, or corticosteroid therapy, as well as organ transplantation, autoimmune and inflammatory conditions, in critically ill patients, and those with chronic obstructive pulmonary disease (COPD) [8, 37]. In about 50% of patients with invasive pulmonary aspergillosis, the infection spreads to other anatomical sites, such as the brain, liver, kidneys, or the gastrointestinal tract [8, 10, 13, 19, 25].
An uncommon clinical form of IA is an isolated invasive Aspergillus tracheobronchitis (iIATB), in which fungal infection is limited predominantly or entirely to the tracheobronchial tree [19, 38]. It has been mainly reported in lung- and heart-lung transplant recipients. Wu et al. reviewed 19 cases of this disease and concluded that iIATB occurs in moderately or nonimmunocompromised patients with impaired airway structures or defense functions and it may be an early period of invasive pulmonary aspergillosis [38]. Early diagnosis and effective antifungal treatment were linked to a favorable prognosis; however, 5 out of 19 (26.3%) patients died.
Other forms of Aspergillus infection of the lungs comprise chronic necrotizing aspergillosis, which is described in patients with chronic lung disease or low degree immunodeficiency as a locally invasive disease, as well as aspergilloma usually found in individuals with previously formed cavities in the lungs [8, 12].
As mentioned earlier, symptoms of the pulmonary disease may result not from actual infection, but allergic reaction of the host to the presence of Aspergillus in the bronchial tree—allergic brochopulmonary aspergillosis (ABPA) [12, 26]. This immunologically mediated disease occurs predominantly in patients with asthma, atopy, and cystic fibrosis (CF) [8, 12, 26].
Aspergillosis of the brain (cerebral aspergillosis) is usually a part of the disseminated disease after hematogenous spread of infection from the lungs, but rarely it may represent an isolated disease of the central nervous system (CNS) [19]. It is reported in 10–15% of patients with invasive pulmonary aspergillosis [39]. The most common risk factors comprise neutropenia and other forms of immunosuppression and transplantation surgery [19]. Cerebral aspergillosis usually presents as a single or multiple brain abscess, also as cerebral vasculitis and cerebral infarcts, while meningitis is rare [19]. Brain abscesses are common in HSCT recipients, while relatively rare in solid organ transplant (SOT) recipients [40, 41]. CT and MRI are recommended in patients in whom cerebral aspergillosis is suspected [42]. Among all types of IA, brain aspergillosis has the worst prognosis, with mortality rate usually exceeding 90% (up to 100%), however early and proper treatment improves the prognosis in these patients and significantly increases their survival rates [19].
Aspergillosis of the CNS may also present as rhinocerebral aspergillosis, particularly in patients with underlying malignancies and neutropenia, HSCT recipients, and patients with diabetic ketoacidosis [37]. Symptoms usually comprise fever, nasal or sinus congestion or pain, nasal discharge, unilateral facial swelling, and headaches [37]. Necrotic lesions may be seen on the hard palate and in the nasal cavity. The spread of infection may lead to ophthalmic complications, such as ptosis, proptosis, and vision disturbances [37].
Invasive cardiac aspergillosis may present as endocarditis, myocarditis, pericarditis, mediastinitis, septic thrombophlebitis, and infections of aortic grafts—also in transplant recipients [5, 6, 43, 44].
Endocarditis caused by Aspergillus spp. is a severe form of fungal endocarditis [45, 46]. The mortality rate is high and surgery is usually required [19, 45, 46, 47]. It is very rare, but in recent years, the incidence of this form of aspergillosis is increasing, due to a rise in the frequency of its risk factors—the use of invasive procedures involving the heart, cardiac surgery with replacement of the heart valves, implantation of cardiac devices, organ transplantation, drug abuse, or administration of immunosuppressive therapy [19, 45]. Pierrotti and Baddour analyzed mold-related endocarditis in 3939 patients (the majority of cases were caused by Aspergillus spp.) and found the following risk factors: underlying cardiac abnormalities (41%), prosthetic heart valves (39%), malignancy (18%), solid-organ transplantation (18%), and bone marrow transplantation (18%) [47]. In a study by Paterson et al., 26% of cases of infective endocarditis occurring within a month of solid organ transplantation were caused by Aspergillus [48]. Woods et al. found that the most common predisposing factors for Aspergillus endocarditis in 29 patients were corticosteroid therapy (55%), prolonged antibiotic treatment (31%), hematological malignancy (28%), and chemotherapy and cytotoxic therapy (28%) [49].
In the course of Aspergillus endocarditis, mitral and bicuspid valves (native or prosthetic) are most often affected [19, 46, 50, 51]. Fungal vegetations may be formed on the heart valves, which subsequently may cause embolism blocking the arteries. Gumbo et al. reported that vegetations were revealed on the heart valves in 78% of the cases in which echocardiography was performed, while embolic episodes were seen in 69% of patients with Aspergillus endocarditis, and a new or changing heart murmur—in 41% of them [52]. In a recently published study, Meshaal et al. showed that aortic abscess or pseudoaneurysm was one of the strong predictors of Aspergillus endocarditis [45]. However, it should be noted that Aspergillus endocarditis may be difficult to diagnose because blood cultures are usually negative, while fever is absent in 26% of patients with this disease [19, 45]. Aspergillus endocarditis should, therefore, be suspected in patients with underlying immunosuppression, hematological malignancies, recent cardiothoracic surgery, intravenous drug use, systemic or pulmonary emboli with negative blood cultures, and vegetation on echocardiography [24]. Diagnosis should be confirmed by histology and mycological culture of tissue or vegetation samples [24]. Delayed or erroneous diagnosis of Aspergillus endocarditis contributes to incorrect management of patients. Early surgical replacement of an infected valve and prolonged administration of antifungal therapy (which may be lifelong) are recommended to prevent embolic complications, valvular decompensation, and further spread of the infection [5, 6, 24, 43, 44].
Heart muscle may be affected by Aspergillus infection in the form of myocarditis or cardiomyopathy [53, 54]. This form of disease usually results from hematogenous spread of infection and is characterized by the presence of abscesses. Pericarditis caused by Aspergillus spp. has been described, also in transplant recipients [43, 55].
Aspergillosis of the eye may take a form of fungal keratitis, endophthalmitis, or invasive aspergillosis of the orbit. All structures of the eyeball may be affected—eyelids, conjunctivae, lacrimal apparatus, cornea, sclera, or uvea. Aspergillus dacryocystitis is a rare complication of aspergillosis of the paranasal sinuses [56]. Clinicians must be aware that the clinical course of ocular aspergillosis may range from asymptomatic infection or slowly developing disease to rapidly progressive infection, with a fulminant course and fatal outcome [56].
Fungal keratitis often presents as a corneal ulcer, which results from mechanical injury of the cornea, with subsequent necrosis. In a recent study, Manikandan et al. examined a total of 500 corneal scrapings, collected from patients in whom mycotic keratitis was suspected, out of which 68 (13.6%) were positive for Aspergillus spp. [57].
Endophthalmitis may be a complication of surgical procedures or may result from hematogenous spread from other sites of infection. Endogenous Aspergillus endophthalmitis is mainly reported in severely immunocompromised patients, transplant organ recipients, patients after heart valve replacement, and in oncohematological patients [58, 59, 60].
Orbital invasive aspergillosis is a rare infection, which most often results from dissemination of the infection from the nose or paranasal sinuses. It may take an acute or chronic form. This form of IA usually presents with a severe orbital pain, paralysis of the oculomotor nerve and visual impairment. Ophthalmic complications, such as ptosis, proptosis, and vision disturbances may result from the spread of infection in rhinocerebral aspergillosis [37].
Aspergillosis of the urinary tract is relatively rare. In immunocompromised patients, such as kidney transplant recipients, frequency of this form of aspergillosis amounts to only 0.5–2.2%, but is fatal in >88% of patients [61]. Urinary tract aspergillosis may also be a complication of surgical procedures, such as lithotripsy, urinary tract instrumentation, or ureteric stenting, particularly in immunocompromised patients [62, 63, 64, 65]. Renal aspergillosis is being occasionally reported with obstruction of one or both ureters [19]. Localized aspergillosis of the renal graft was reported in a child 5 months after kidney transplantation [61]. A case of urinary tract aspergillosis presenting as an aspergilloma of the urinary bladder has also been described [66].
Aspergillosis of the genital tract has been rarely reported [67, 68, 69]. In women, it may give the symptoms resembling a pelvic inflammatory disease.
Other clinical forms of aspergillosis—apart from above-mentioned—are very rare and comprise gastrointestinal aspergillosis, cutaneous aspergillosis, Aspergillus peritonitis, osteomyelitis, and septic arthritis, as well as Aspergillus ear infections [5, 6, 19, 37].
Gastrointestinal aspergillosis is mainly reported in patients who are transplant recipients or severely malnourished [37]. It results from ingestion of Aspergillus spp. spores. The most commonly involved sites are the stomach, colon, and ileum.
Cutaneous aspergillosis is classified as primary or secondary [37]. Primary form of the disease is usually reported in patients with burn wounds or surgical wounds. This clinical entity is caused by direct inoculation of the fungus or its spores into the injured skin [37]. Primary cutaneous aspergillosis has been linked to leukemic patients, neonates, transplant recipients, as well as the use of occlusive dressings or permanent intravenous catheters [19]. Secondary cutaneous aspergillosis results from hematogenous spread of the fungus and therefore represents a disseminated form of Aspergillus infection. It may present as nodules or extensive necrotic lesions [19]. The mortality rate may be high.
Aspergillus peritonitis is seen in patients undergoing peritoneal dialysis [19]. It may be complicated by hemorrhage, perforation, or infarction.
Aspergillus ear infections may present as noninvasive otitis externa (otomycosis) or invasive aspergillosis of the ear. Examples of other forms of invasive aspergillosis comprise vertebral osteomyelitis (resulting from hematogenous spread, by contiguity or from direct inoculation), septic arthritis, cholangitis, and prosthetic vascular graft rejection [19].
Disseminated aspergillosis if defined as the involvement of at least two noncontiguous sites in the body, mainly in transplant recipients [19]. Disseminated disease has been reported in 9–36% of kidney transplant recipients, 15–20% of lung transplant recipients, 20–35% of heart transplant recipients, and 50–60% of liver transplant recipients with invasive aspergillosis [70].
In patients with immune deficiencies and other risk factors, invasive aspergillosis (IA) is a life-threatening infection caused by the opportunistic molds of the genus Aspergillus, most often by A. fumigatus [5, 6, 14, 70, 71]. A cohort study of 960 cases of probable or proven IA reported in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry, indicated that 48.3% of patients had hematologic malignancy, 29.2% were SOT recipients, 27.9% were HSCT recipients, and 33.8% were neutropenic [12]. In these patients, the most common clinical forms of IA are invasive pulmonary aspergillosis (IPA) and rhinocerebral aspergillosis [12].
In transplant recipients, particularly in hematopoietic stem cell transplant (HSCT) recipients who are severely immunocompromised, invasive aspergillosis is not only more common than in other groups of patients, but is also characterized by much more severe and rapidly progressive clinical course, and much higher mortality [12, 72].
Although prognosis has improved in recent years, IA still remains a significant post-transplant complication in solid organ transplant (SOT) recipients [43, 44]. It occurs in up to 30% of SOT recipients. Although in recent years the mortality rate in transplant recipients decreased from 65–92% to 22%, still an estimated 9.3–16.9% of all deaths in transplant recipients in the first year after transplantation can be attributed to IA [44].
The incidence of IA differs between different populations of transplant recipients, and unique risk factors for Aspergillus infections have been identified for various types of organ transplant recipients [43, 44]. However, regardless of the type of transplantation a major risk factor for the development of IA in SOT recipients is the net state of immunosuppression including the intensity of administered immunosuppressive therapy [44].
Regarding the risk of invasive fungal infections (particularly IA) in transplant recipients, at present routine antifungal prophylaxis or preemptive therapy is recommended in HSCT recipients with prolonged neutropenia or graft-versus-host disease (GVHD), and in lung transplant recipients, while targeted prophylaxis should be considered in liver and heart transplant recipients [5, 6, 44, 71].
Invasive aspergillosis remains a major complication following allogeneic HSCT (alloHSCT) [73]. The burden of IA has increased significantly in the last 30 years as a result of the increased number of patients undergoing immunosuppressive therapy for hematological malignancies and HSCT [14]. It is estimated that IA is a leading cause of fatal outcomes in HSCT patients, accounting for 10% of all deaths in this group of patients [14].
In the recipients of alloHSCT, IA can occur during the neutropenic pre-engraftment phase (early IA) or during the post-engraftment period (late IA) [14]. Although IA remains an important complication after allogeneic transplantation, regardless of the type of conditioning regimen, early IA is more common in patients undergoing myeloablative transplantation due to extensive chemotherapy and radiation used to destroy the native bone marrow, and prolonged neutropenia which results from this treatment [14, 74]. On the other hand, non-myeloablative HSCT comprises a shorter neutropenic period and therefore, a decrease in the incidence of early IA. However, a higher risk of GVHD in this group of patients and the therapies given for this condition caused a shift to late IA, diagnosed increasingly during the post-engraftment period [14]. It should be noted that the risk period for late IA, associated with GVHD, can last for months to years, so prophylactic and monitoring procedures must be implemented over a long period. Carvalho-Dias et al. analyzed 24 cases of proven and probable invasive aspergillosis among HSCT recipients and reported, that 83% of the patients died due to invasive fungal infection within 60 days of follow-up [72].
Kojima et al. compared the incidence of IA and mortality rates due to this disease in 664 recipients of alloHSCT—486 conventional stem cell transplantation (CST) patients and 178 reduced-intensity stem cell transplant (RIST) recipients. The overall incidence of IA in all 664 recipients of alloHSCT was 35 (5.3%) [74]. Despite significant differences in the estimated 3-year incidence of IA in CST group (4.5%) and RIST population (8.2%) (P = 0.045), the mortality rates were similar in both groups (76 and 86%, respectively). However, the median onset of IA after RIST was day 127, which was significantly later than that after CST—day 97 [74]. Furthermore, a multivariate analysis showed that IA was associated with age > 50 years and the presence of acute or chronic GVHD [74]. In another study, Labbe et al. analyzed the risk factors for IA in 125 alloHSCT recipients with nonmyeloablative (NMA) regimens, who received a 6/6 matched sibling NMA HSCT and were treated homogenously [73]. IA developed in 13 patients (5 proved, 6 probable, and 2 possible IA), at 44–791 days (median 229 days) after NMA HSCT. The risk of IA was calculated as 7% at 1 year, 11% at 2 years, and 15% at 3 years after NMA alloHSCT [73]. It was concluded that in NMA HSCT recipients the risk of IA increases over time and is significantly associated with intestinal GVHD, therefore these patients should be monitored for this complication and administration of antifungal prophylaxis with activity against molds should be considered [73].
In lung transplant recipients, invasive aspergillosis is the predominant fungal infection [44, 71, 75]. In the past, the incidence of IA in this group of patients was reported in the range of 4.0–23.3%, however, newer studies point to a lower frequency of this disease [44]. On the other hand, the time from lung transplantation to the onset of IA becomes longer due to the use of antifungal prophylaxis in the early post-transplant period. Therefore the median time to IA onset has increased from 120 days post-transplant to 483 or 508 days post-transplant reported in recent studies [44].
The most common species linked to the etiology of IA in lung transplant recipients is Aspergillus fumigatus. In an international, multicenter, retrospective cohort study of 900 consecutive adult lung transplant recipients with 4 years of follow-up, 79 patients developed 115 episodes of IA [75]. Aspergillus fumigatus was isolated in 72 of 115 (63%) episodes [75]. In a retrospective study of 251 lung transplant recipients, Aspergillus was isolated from 86 (33%) cases including 50 patients colonized with Aspergillus spp., 17 recipients with tracheobronchitis, and 19 cases of IA [76]. These authors reported that isolation of Aspergillus spp. from respiratory samples preceded acute rejection of the graft, therefore it may be a marker of threatening graft rejection and/or inflammation of the airways [76].
The significance of the patient’s airway colonization with Aspergillus spp. before lung transplantation remains controversial. Some authors indicate its importance within the first year after lung transplantation, if the recipient was colonized in the period of 6 months before lung transplantation, while others did not find any significant link between Aspergillus pre-transplant colonization and occurrence of IA in the post-transplant period [44, 75, 76, 77]. Other risk factors for IA, which are unique to lung transplant recipients, comprise bronchial anastomotic leaks and other complications within the surgical site, airway narrowing, allograft dysfunction and/or graft ischaemia, reperfusion injury, CMV infection, bronchiolitis, and requirement for more intensive immunosuppressive therapy to prevent graft rejection [44, 76]. In lung transplant recipients, recovery of Aspergillus spp. from a respiratory tract sample warrants bronchoscopy to exclude the presence of tracheobronchitis [44].
It should be beared in mind that in lung transplant recipients there is a continuous exposure of the graft to the external environment through the airways, with impaired defense mechanisms (decreased mucociliary function, weakened cough reflex) in the early postransplant period [44].
In lung transplant recipients, there is a transient devascularization of the bronchial anastomotic site, which may contribute to ischemic injury and necrosis. This is a risk factor for development of ulcerative tracheobronchitis—a locally invasive form of IA involving the anastomotic site, the trachea, and the bronchi [44, 78]. In these patients, bronchovascular fistulas may develop, with a potentially fatal hemorrhage.
In the literature reports, the mortality rate of lung transplant recipients with IA ranges from 23 to 29% in individuals with tracheobronchitis to as high as 67–82% in patients with invasive pulmonary aspergillosis, but according to some estimates at present, it could be as low as 20% [44]. In a follow-up study of 251 lung transplant recipients, Aspergillus infection was associated with a reduced 5-year survival rate of these patients [76]. Prognosis is worse in patients with aspergillosis of the central nervous system or with disseminated disease [71].
According to the literature, the incidence of invasive aspergillosis in heart transplant recipients ranges from 1 to 14% [44, 79]. In this population, the risk factors for IA comprise isolation of Aspergillus fumigatus from bronchoalveolar lavage fluid, disease caused by cytomegalovirus, reoperation, and post-transplant hemodialysis [44]. The mortality rate in heart transplant recipients with invasive aspergillosis remains high—in the range of 66–88% [44, 79, 80, 81].
Invasive pulmonary aspergillosis remains the most common clinical presentation of this disease, particularly in early-onset IA (≤3 months after transplantation), while in late-onset IA, there is a higher frequency of disseminated disease and involvement of the central nervous system and other extrapulmonary sites [79, 80]. In an analysis of 455 heart transplant recipients, in whom 8 cases of IA have been diagnosed, all had invasive pulmonary form of the disease [79]. Risk factors for early-onset IA (within ≤3 months after heart transplantation), comprised hemodialysis, thoracic reoperation, and the presence of another case in the institution within the preceding 3 months [79]. For late-onset IA in this population of heart transplant recipients, hemodialysis and augmented immunosuppression were identified as risk factors [79]. In the clinical course of these cases, predominated septic shock and multiple organ dysfunction syndrome (MODS), nonspecific clinical and radiographic findings, as well as rapid (at a median of 11 days after diagnosis) mortality despite administration of antifungal therapy with activity against molds [79]. In a study by Montoya et al., none of the heart transplant recipients with either invasive pulmonary aspergillosis or invasive extrapulmonary aspergillosis had neutropenia [81]. Therefore, even in the absence of neutropenia invasive pulmonary aspergillosis should be suspected, particularly within the first 3 months of transplantation in heart transplant recipients who have fever and respiratory symptoms, a positive result of culture of respiratory secretions, and abnormal radiological findings (particularly nodules) [81].
A study of 479 consecutive heart transplant recipients in a single institution revealed a decrease in the incidence of IA from 8.7% (24/277) in the period 1988–2000 to 3.5% (7/202) in 2001–2011 [80]. Overall the incidence of IA in the studied group of heart transplant recipients was 6.5% (31 of 479). However, the authors report that four of seven cases were diagnosed as an outbreak, which indicates that favorable conditions for an infection with Aspergillus spp. may be present in a hospital [80]. Over the study period, there was a decrease in the mortality rate among the heart transplant recipients with IA from 46 to 0% (p = 0.04) [80]. The authors also noted a higher mortality rate in late-onset IA cases (63%) in comparison to early-onset IA (26%, p = 0.09) [80].
Invasive aspergillosis is reported in 1.0–9.2% of the liver transplant recipients. Mortality rates have decreased from 83–88% in earlier studies to 33–65% in more recent reports [44]. However, they remain very high in patients who develop invasive aspergillosis after liver retransplantation (82.4%), particularly in those undergoing surgery later than 30 days after primary liver transplantation (100%) [44].
Risk factors for invasive fungal infections, including aspergillosis, in these patients, comprise retransplantation (30-fold higher risk) and renal dysfunction, particularly requiring any form of renal replacement therapy (15- to 25-fold higher risk) [44]. Furthermore, transplantation for fulminant hepatic failure, pretransplant corticosteroid therapy, cytomegalovirus (CMV) infection, and prolonged intensive unit care stay are other risk factors associated with invasive aspergillosis in liver transplant recipients [44]. It is underlined that liver transplant recipients are particularly susceptible to disseminated and central nervous system invasive aspergillosis [44].
Previously most invasive fungal infections in liver transplant recipients occurred within the first month after transplantation (the median time to onset was reported as 16–17 days), however, in recent years, they are usually diagnosed in the late period (>90 days) after liver transplantation. After renal replacement therapy and retransplantation, the median time to onset of IA was reported as 13 and 28 days, respectively [44].
Invasive aspergillosis has been reported in 0.7–4.0% of the renal transplant recipients [44]. It should be emphasized that despite a relatively low overall incidence of IA in comparison to other solid organ transplant (SOT) recipients, the mortality rate is high in these patients—in the range of 67–75% [44]. Risk factors for invasive aspergillosis in kidney transplant recipients are the following: potent immunosuppressive therapy, leukopenia, prolonged and/or high dose corticosteroid therapy, longer duration of renal replacement therapy in the pretransplant period, and graft failure requiring hemodialysis [44, 82].
In a recent study, Desbois et al. analyzed the outcome of IA in kidney transplant recipients in the era of voriconazole availability [83]. Unfortunately, they concluded that the prognosis of patients with IA after renal transplantation is still poor, and even if the patients survive, the risk of graft loss is high [83].
The diagnosis of invasive aspergillosis remains a significant challenge [19]. It is usually based on a histopathological evidence of tissue invasion, in conjunction with an isolation of Aspergillus spp. in culture of the biopsy material or other clinically relevant specimen, as well as compatible clinical signs and symptoms in a patient with recognized risk factors. Imaging examinations (radiographic, computed tomography, and magnetic resonance), as well as serological tests (detection of fungal antigens and antifungal antibodies), provide only additional information and should be interpreted in conjunction with the clinical picture and the results of additional laboratory tests [13, 19, 48].
It should be emphasized that fast detection and identification of the etiological agent of infection is of utmost importance as it allows an early start of an effective antimicrobial therapy, which improves the patient’s chances to survive.
In mycological diagnostics, the culture of the fungus from the site of infection and in vitro susceptibility testing of the isolate remain the “gold” standard. A diagnosis of invasive pulmonary aspergillosis comprises detection of the fungal mycelium with histopathological (with the use of different staining techniques) tests and/or positive culture of the relevant material obtained from the lower respiratory tract [5, 6, 13, 15, 19]. In a patient in whom invasive pulmonary aspergillosis is suspected, it is recommended to culture a sample of bronchoalveolar lavage fluid (BALF), obtained as early as possible during the course of infection [5, 6, 13, 19]. It should be emphasized that the result of sputum culture is not an unequivocal proof of invasive infection of the lung parenchyma, because it may represent only colonization of the respiratory tract by the isolated microorganism. It has been reported that among 66 elderly patients in whom Aspergillus spp. was cultured from sputum, only 3 individuals had invasive pulmonary aspergillosis [84]. In another study, no Aspergillus spp. was cultured from the sputum of 70% of patients with invasive pulmonary aspergillosis confirmed with other reliable methods [8].
Blood cultures are rarely positive in patients with invasive pulmonary aspergillosis [8, 19, 45]. In patients with pulmonary aspergillosis, Aspergillus fungaemia was detected in 10.1% (9/89) of them, at a median of 5 days from the onset of clinical symptoms [19]. The diagnostic role of Aspergillus fungaemia in patients with an invasive form of infection is limited because blood cultures become positive (if at all) in the late stage of the disease when a microbiological or clinical diagnosis has already been made [19].
In laboratory diagnostics of this form of aspergillosis, detection of Aspergillus spp. antigen—galactomannan (GM)—in BALF or in serum, may be useful; however, it should be remembered that it could represent a false positive result [10, 13, 15, 19, 29]. Detection of another fungal antigen which is a constituent of the fungal cell wall—(1–3)-β-D-glucan (BDG)—is a nonspecific marker of fungal infection, being positive in many fungal infections apart from aspergillosis [13]. Molecular methods (e.g. detection of DNA of the strains classified in the genus Aspergillus in blood or BALF using PCR technique) are promising, however at present, they are not routinely available in clinical microbiology laboratories, and interpretation of their results requires further analyses [13, 19, 85]. Research is ongoing on the usefulness of serum interleukin-8 concentration as an auxiliary marker in laboratory diagnostics of invasive pulmonary aspergillosis [86]. Therefore, it should be emphasized that diagnosis of invasive pulmonary aspergillosis requires evaluation of the patient’s clinical status in conjunction with the results of various examinations—imaging, histological, and mycological, as well as biochemical markers [1, 8, 13, 15, 86].
Laboratory methods currently used in diagnosis of invasive aspergillosis comprise three groups of techniques: detection of fungal invasion in histopathological examination of tissue sections; direct microscopy and isolation of Aspergillus spp. in culture of the clinically relevant samples; and noninvasive methods such as serological detection of antigens or nucleic material of Aspergillus spp., or detection of antibodies [19, 87].
Histopathological examination of biopsy or autopsy tissue sections confirms the fungal etiology of invasive infections [1, 5, 6, 13, 15, 19]. Tissue sections are usually stained with hematoxylin and eosin, but other staining techniques are also used in practice (e.g. Gomori-Grocott methenamine silver stain, periodic acid-Schiff stain) [2, 88, 89]. Histopathological tissue sections from a patient with invasive easpergillosis of the heart and lung are shown in Sulik-Tyszka et al. [89].
In tissue sections, Aspergillus appears as septate hyphae, with dichotomous branching at 45° angles suggestive of Aspergillus spp. [2, 19]. Conidiophores and fruiting bodies are rarely seen, except in areas exposed to air, for example, bronchi [19]. Invasive lesions are characterized by an area of necrosis and non-caseating granulomatous inflammation. A characteristic feature of invasive aspergillosis is trespassing of the the fungus into the blood vessels, with subsequent infarction and tissue necrosis.
Clinical samples for isolation of Aspergillus spp. in culture depend on the clinical symptoms and suspected localization of infection. In the diagnosis of invasive pulmonary aspergillosis, a lung biopsy or a sample of BALF is recommended. Other specimens, such as bronchial or endotracheal aspirates, pleural fluid, and also sputum may be cultured as well [5, 6, 19]. Blood cultures can be done, but are usually negative. In fact, any suspicious lesion (e.g. cutaneous or skeletal) should be biopsied and cultured for fungi [19].
The direct microscopic examination allows not only rapid detection of the fungus directly in the specimen, but also its preliminary identification.
A universal solid medium for culturing fungi is Sabouraud agar. When culturing a sample obtained from a site which is primarily nonsterile, Sabouraud agar supplemented with chloramphenicol and gentamicin is used. Czapek-Dox agar and 2% malt extract agar are also used, as well as liquid media [19]. Commercially available media are recommended in order to standardize the culture methods.
Identification of the isolates belonging to the genus Aspergillus relies on evaluation of the colony morphology and color (both on the upper and reverse sides of the agar plate), and diffusion of the pigment into the medium (Figure 1). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) technique may be used in the identification of Aspergillus spp. and is a promising tool, particularly for the identification of rare species of Aspergillus [90, 91]. This method allows a rapid and reliable identification of the isolate and therefore, an early start of effective antifungal therapy.
Aspergillus spp. growth on Sabouraud agar. (A) Aspergillus niger; (B) Aspergillus fumigatus; (C) Aspergillus flavus.
Interpretation of the mycological culture results is important and depends on the clinical picture [19]. In a routine microbiology laboratory work, most of the isolates of Aspergillus fumigatus do not indicate proven or probable infection. However, cultures positive for Aspergillus fumigatus, in the appropriate epidemiological and clinical setting, such as highly immunocompromised transplant recipients, are strongly associated with the presence or risk of IA and therefore should not be disregarded [19]. Also, the isolation of Aspergillus fumigatus in hematological patients, even from nonsterile samples, is generally regarded as potentially significant [19]. It has been reported that in heart transplant recipients with suspicion of invasive aspergillosis, a culture positive for Aspergillus has a positive predictive value (PPV) of 60–70% [92]. Higher PPV (78–91%) was linked to the isolation of Aspergillus fumigatus, with a further increase to 88–100% when Aspergillus fumigatus is recovered from a respiratory specimen other than sputum [92].
It should be emphasized that in transplant recipient’s fungal cultures may be negative, despite disseminated infection, and in invasive aspergillosis, blood cultures are usually negative, even in patients with Aspergillus endocarditis [19].
Serological tests are widely used in the laboratory diagnostics of aspergillosis. Conventional methods, such as culture of clinical samples and direct microscopy of the specimens, have low sensitivity and may give positive results in the late stages of the disease [19]. Furthermore, suitable specimens for these methods may be difficult to obtain in severely ill, immunocompromised patients. In recent years, serological techniques are being used increasingly on such specimens, like serum or BALF, for detection of fungal antigens (e.g. galactomannan, (1,3)-ß-d-glucan) and anti-galactomannan antibodies against Aspergilllus [44]. Detection of galactomannan in BALF or serum is at present recommended in the American and European guidelines on laboratory diagnosis of invasive aspergillosis in immunocompromised patients [5, 6, 13].
Duration of antifungal therapy may be guided not only by monitoring of galactomannan levels, but also by the clinical status of the patient and radiological findings.
Galactomannan (GM) is a cell wall component of Aspergillus spp., released from Aspergillus hyphae, while they invade the host tissue, and therefore, it is a specific marker of this fungus [19]. This test may be helpful in early diagnosis of IA (median of 6 days before the symptoms appear) before the infection becomes disseminated [19]. Galactomannan can be detected with the use of latex tests (detection level 15 ng/ml) or more sensitive immunoenzymatic assays, in which 1 ng/ml of GM can be detected. Variation in sensitivity of these tests is being reported, which may due to the different cut-off values for a positive GM result in Europe (1.5 ng/mL) and the USA (0.5 ng/mL) [19].
Galactomannan concentration in the bronchoalveolar lavage fluid, in combination with other diagnostic tests (e.g. chest CT scan or mycological culture) is recommended as a test for the diagnosis of IA in lung and nonlung transplant recipients [71]. Galactomannan in BALF sample has proven superior to serum testing with high sensitivity (67–100%) and specificity rates (91–100%) for the diagnosis of invasive aspergillosis in lung transplant recipients [44]. In patients with prolonged neutropenia and allogeneic stem cell transplant recipients during the early engraftment phase, GM detection is commonly used, and serial screening for GM in serum has a high sensitivity and a negative predictive value for IA [13, 14]. However, serial screening for GM is not recommended in patients receiving antifungal prophylaxis with anti-Aspergillus spectrum of activity [13].
False-positive results of galactomannan detection have been documented in up to 13–29% of the liver transplant recipients and in 20% of the lung transplant recipients [44]. In the liver transplant recipients, false-positive results of galactomannan tests were more often seen in patients with transplantation for autoimmune liver disease, perioperative prophylaxis with β-lactam antibiotics, and requirement of dialysis. Most false-positive tests after lung transplantation occurred in the early post-transplant period: that is, in 43% within 3 days, in 64% within 7 days, and in 79% within 14 days of surgery. False-positive results of galactomannan detection are linked to several factors, such as antibiotic therapy with specific groups of antibacterials (such as some cephalosporins, carbapenems, amoxicillin-clavulanate, ampicillin/sulbactam, and piperacillin/tazobactam), cyclophosphamide therapy, as well as administration of blood products, albumin or immunoglobulins, or the use of cellulose hemodialysis membranes [93, 94].
Detection of (1,3)-ß-d-glucan is a nonspecific test for fungal infection, as it is one of the main cell wall polysaccharide components of many fungi [19]. Available diagnostic tests are characterized by a high sensitivity and specificity and enable detection of (1,3)-ß-d-glucan at the concentration of >1 pg/ml. It has been reported that in living-donor, liver allograft recipients, detection of (1,3)-ß-d-glucan was useful for the diagnosis of invasive aspergillosis [95]. Several factors have been linked to false-positive results of the tests for (1,3)-ß-d-glucan, which are similar to those for galactomannan detection [19].
At present, molecular diagnostic tests for Aspergillus spp. are not available in routine clinical microbiology laboratories, however, in the near future, they will be used increasingly, particularly for identification of unusual species, with specific profiles of susceptibility or resistance to antifungals [19, 44, 96]. Recently, PCR technique for detection of Aspergillus spp. has been extensively validated and will be included in the diagnostic criteria in the revised European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC-MSG) definitions [97]. A comprehensive review of the molecular diagnosis of invasive aspergillosis has recently been published [85].
The majority of molecular methods which can be used in the clinical microbiology laboratories are based on PCR technique. These methods are particularly useful for testing of lung specimens. It has been reported, that quantitative PCR test used for diagnosis of IA with a sample of bronchoalveolar lavage fluid was characterized by 67% sensitivity and 100% specificity [98]. Perhaps in the future, quantitative PCR tests will also be used to monitor the response to antifungal treatment in patients with IA [19].
Fluorescence in situ hybridization-based molecular method is a promising approach in the A. fumigatus detection in the tissues [87]. Species identification of Aspergillus isolates may be made by β-tubulin and calmodulin gene sequencing [91]. Further analyses are needed to evaluate the significance of the results of molecular tests in immunocompromised patients suspected of invasive aspergillosis.
Successful treatment of invasive aspergillosis comprises early diagnosis of the disease, selection of an appropriate antifungal agent active against fungi of the genus Aspergillus, and prompt initiation of antifungal therapy, as well as surgical debridement, particularly in immunocompromised patients, such as HSCT and SOT recipients [3, 44]. Proper pharmacokinetics, pharmacoeconomics, and no interactions with other medications (e.g. immunosuppressants) administered to the patient are further factors which determine the choice of a proper antifungal agent.
At present, there are three groups of antifungal agents, which can be used in the therapy of aspergillosis: azoles, polyenes, and echinocandins [99]. The choice of treatment regimen depends on several factors, including the host’s immune status, liver, and kidney functions, and prior antifungal therapies [99]. Treatment regimens of invasive aspergillosis are shown in Figure 2.
Treatment of invasive aspergillosis.
It should be emphasized that in the choice of proper antifungal therapy, susceptibility testing of the cultured isolate is important in view of an emerging resistance of some Aspergillus strains to azoles, as well as identification to the species level, as resistance to antifungals is more likely with certain species of Aspergillus other than Aspergillus fumigatus [99]. For example, A. terreus has a high minimum inhibitory concentration (MIC) to amphotericin B, while A. calidoustus has to numerous antifungals [99]. The role of a combination antifungal treatment for primary therapy of IA remains controversial; however, it may be considered (e.g. voriconazole with an echinocandin) for treatment of infection caused by these species [71, 99].
Apart from antifungal therapy, surgery may be indicated in patients with invasive aspergillosis. It applies to the cases in which the disease is localized and infection site is easily accessible to debridement (e.g. invasive fungal sinusitis or localized cutaneous lesions) [5, 6]. Surgical excision or debridement may be used for both diagnostic and therapeutic purposes [44].
Surgery of the sinuses may involve removal of the granulation tissue and necrotic bone [3]. Surgery may also be required in patients with endocarditis, osteomyelitis, or focal lesions in the central nervous system [5, 6]. Surgery is particularly indicated for persistent, or a life-threatening hemoptysis, lesions in the proximity of great vessels or pericardium, nasal and sinus infections, single cavitary lesion in the lung, intracranial abscesses, as well as lesions invading the pericardium, bone, the subcutaneous, or thoracic tissue [100].
According to the newest guidelines of ECIL-6 (the European Conference on Infections in Leukemia), recommendations of Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases, European Confederation of Medical Mycology, European Respiratory Society (ESCMID/ECMM/ERS) as well as expert groups, the drugs of first choice in therapy of invasive aspergillosis are triazoles—voriconazole or isavuconazole in monotherapy [5, 6, 13, 20, 71].
Isavuconazole is as effective as voriconazole, and in addition, it is characterized by a better safety profile, therefore in the newest guidelines, it has been granted AI recommendation equally with voriconazole [5, 6]. In patients who do not tolerate voriconazole, therapy with itraconazole or posaconazole may be considered; however, cross-resistance between azoles may be a problem [5]. An alternative antifungal agent used in the therapy of this disease is liposomal amphotericin B [5, 6, 13, 71]. It is emphasized that the chosen agent should be implemented as quickly as possible after fungal etiology of the infection has been suspected [5, 15]. At present, the routine use of combination therapy is neither recommended as a first line treatment, nor the use of echinocandins as the primary treatment [5].
In recent years, an increase in the percentage of strains of Aspergillus fumigatus resistant to azoles (including voriconazole) is being observed, which may pose a therapeutic problem [20, 101, 102, 103]. Resistance is mainly due to mutations in the gene cyp51A and/or overexpression of the efflux pumps in the cells of these fungi [101, 102, 103, 104, 105, 106]. Lestrade et al. showed that among 196 patients with IA, in 37 (19%) infection was caused by a strain of A. fumigatus resistant to voriconazole, which was linked to >20% increase in the mortality rate in this group of patients in comparison to individuals who received proper antifungal treatment [107]. In 2006–2016, Borman et al. analyzed 2501 clinical strains of Aspergillus fumigatus, among which 3.1% were resistant to voriconazole and 12.5% were resistant to amphotericin B [108]. The range of MIC values for these strains to voriconazole was 0.03–16.0 μg/ml and to amphotericin B was 0.06–4.0 μg/ml [108]. In a study comprising 105 clinical strains of Aspergillus fumigatus, a significant difference was reported in the percentage of strains resistant to triazoles among the isolates cultured from samples obtained from hematological patients (15.9%), in comparison with the group of patients treated in the ICU (4.5% strains) [101].
Voriconazole has emerged as the preferred agent for primary therapy of IA. Its efficacy has been confirmed in many studies, including hematopoietic stem cell transplant recipients and patients with hematological malignancies, as well as SOT recipients [44]. Voriconazole was effective in heart transplant recipients, in SOT recipients with central nervous system aspergillosis. In a lung transplant patient with Aspergillus endophthalmitis, voriconazole has been used in the form of an intravitreal injection [44].
An alternative antifungal agent recommended in therapy of IA is liposomal amphotericin B (L-AmB), which is active in vitro against the majority of strains of Aspergillus [5, 6, 13, 44, 71, 99]. However, it should be remembered that some species of Aspergillus (e.g. A. terreus) neutropaenic patients may be resistant to this antifungal agent.
Echinocandins (caspofungin, micafungin, or anidulafungin) are not recommended as first-line therapy of invasive aspergillosis, as they exhibit only fungistatic (not fungicidal) activity against the isolates of Aspergillus spp. They can be considered in salvage therapy; however, in combination with voriconazole, isavuconazole, or liposomal amphotericin B [44, 99, 109].
In patients not responding to monotherapy with antifungal agents recommended as first-line therapy, such as voriconazole, isavuconazole, or liposomal amphotericin B, a salvage therapy must be considered, with the use of a combination antifungal regimen [99]. In these cases, it is suggested to combine an echinocandin (caspofungin, micafungin, or anidulafungin) with voriconazole, isavuconazole, or liposomal amphotericin B, while there are no clinical data to support the use of triazoles in combination with amphotericin B [99]. Apart from salvage antifungal therapy, reduction of the doses of immunosuppressive agents (if feasible), as well as surgery should be considered in these patients.
The duration of therapy for IA is usually 12 weeks, but may range from 3 to >50 weeks or may be even lifelong [5, 6, 13, 44]. Many factors may influence it, such as the response to administered therapy, the patient’s immune status and underlying diseases [44]. It is recommended to continue therapy until all clinical and radiographic abnormalities have resolved, and cultures are negative for Aspergillus. In transplant recipients, it is important to lower the doses of immunosuppressive agents, as well as to monitor an allograft function [44]. Patterson et al. and other expert groups recommend that therapy of invasive pulmonary aspergillosis should be continued for at least 6–12 weeks, depending on the site of disease, degree and duration of immunosuppression, and evidence of improvement of the patient’s clinical status [5, 6]. In patients with stable and pharmacokinetically predictable status, physicians should consider switching from intravenous to oral therapy [13]. If immunosuppression has to be continued after successful therapy of invasive aspergillosis, secondary prophylaxis should be initiated to prevent recurrence of the infection [5, 6].
Antifungal prophylaxis against aspergillosis should be used in patients at high risk of IA during prolonged neutropenia [5, 6]. It is recommended to administer posaconazole, voriconazole, or micafungin (caspofungin is also probably effective) [5, 6]. Prophylaxis with itraconazole is effective, but absorption and tolerability of this drug may be a problem.
For allogeneic HSCT recipients with graft-versus-host disease (GVHD), who are at high risk for IA, prophylaxis with posaconazole is recommended, but other azoles active against Aspergillus may also be used [5, 6]. In patients with chronic immunosuppression associated with GVHD antifungal prophylaxis should be continued throughout the duration of immunosuppression [5, 6].
According to the ECIL-6 and other recommendations, antifungal prophylaxis with either a systemic triazole (voriconazole or itraconazole) or an inhaled AmB product is recommended for 3–4 months after lung transplantation [5, 6]. Aerosolized amphotericin B is an option which allows the direct administration of the antifungal agent into the transplanted lung, with avoidance of systemic unwanted effects and drug–drug interactions [44]. However, for certain groups of lung transplant recipients (single lung transplant recipients, mold colonization before or after lung transplantation, mold infections detected in explanted lungs, and fungal infections of the sinus) systemic voriconazole or itraconazole is recommended rather than inhaled AmB. Patterson et al. and other experts recommend reinitiation of antifungal prophylaxis in lung transplant recipients who receive immunosuppression augmentation with thymoglobulin, alemtuzumab, or high-dose corticosteroids [5, 6].
For other SOT recipients, antifungal prophylaxis against IA is not routinely recommended and should be based on the institutional epidemiology of aspergillosis and assessment of the patient’s risk factors [5, 6, 44]. A common approach to antifungal prophylaxis in liver transplant recipients is to target high-risk patients (fulminant hepatic failure, reoperation, retransplantation, or with renal failure), and it is administered during pre-transplant hospitalization and for the first-month posttransplant. Risk factors for IA have also been identified in heart transplant recipients, such as pretransplant colonization with Aspergillus spp., reoperation, cytomegalovirus (CMV) infection, and renal dysfunction. Other risk factors for IA, which may justify antifungal prophylaxis are institutional outbreaks and prolonged or high-dose corticosteroid therapy; however, the optimal duration of such prophylaxis has not been determined [5, 6].
At present, it is recommended to reduce the doses of immunosuppressive therapy administered to the patient (or eliminate it, if possible), as this improves the outcome of anti-Aspergillus therapy [5, 6]. Other approaches can be considered in cases not responding to standard antifungal therapy, such as granulocyte transfusions in neutropenic patients with IA, or recombinant interferon-γ as prophylaxis in patients with chronic granulomatous disease (CGD) [5, 6].
A relatively new approach to the therapy of invasive aspergillosis in immunocompromised patients involves the use of immunomodulatory agents which would enhance the host’s immune system [44]. There is a potential for clinical use of selected cytokines or colony-stimulating factors (e.g. granulocyte colony-stimulating factor, G-CSF; granulocyte-macrophage colony-stimulating factor, GM-CSF; interferon-γ) with immunomodulatory effect [44, 110].
There is an ongoing search for new, more effective antifungals, which will be active also against drug-resistant isolates of Aspergillus spp. Currently, there are new classes of antifungal drugs under development—two agents in phase 2 study for the therapy of systemic invasive fungal infections and one drug in phase 1 [111]. Among them are agents which show activity against resistant to azoles cyp51A mutants of Aspergillus spp.
Diagnosis of invasive aspergillosis remains a challenge for clinicians and microbiologists. Progress in modern diagnostic methods and imaging techniques may contribute to an early and reliable diagnosis of infections caused by Aspergillus spp. This is particularly important in immunocompromised patients, such as HSCT and SOT recipients. Proper choice and early commencement of antifungal therapy increase the chances for survival and recovery of these patients from invasive aspergillosis.
You have been successfully unsubscribed.
",metaTitle:"Unsubscribe Successful",metaDescription:"You have been successfully unsubscribed.",metaKeywords:null,canonicalURL:"/page/unsubscribe-successful",contentRaw:'[{"type":"htmlEditorComponent","content":""}]'},components:[{type:"htmlEditorComponent",content:""}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5717},{group:"region",caption:"Middle and South America",value:2,count:5179},{group:"region",caption:"Africa",value:3,count:1696},{group:"region",caption:"Asia",value:4,count:10260},{group:"region",caption:"Australia and Oceania",value:5,count:890},{group:"region",caption:"Europe",value:6,count:15670}],offset:12,limit:12,total:117458},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateendthirdsteppublish"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:11},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:14},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:4},{group:"topic",caption:"Engineering",value:11,count:16},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:51},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:5},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"6934",title:"Psycho-Social Aspects of Human Sexuality and Ethics",subtitle:null,isOpenForSubmission:!1,hash:"44731b106aa0d1ab5c64a7394483c7d5",slug:"psycho-social-aspects-of-human-sexuality-and-ethics",bookSignature:"Dhastagir Sultan Sheriff",coverURL:"https://cdn.intechopen.com/books/images_new/6934.jpg",editedByType:"Edited by",editors:[{id:"167875",title:"Dr.",name:"Dhastagir Sultan",middleName:null,surname:"Sheriff",slug:"dhastagir-sultan-sheriff",fullName:"Dhastagir Sultan Sheriff"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10062",title:"Forecasting in Mathematics",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"9a3ad05fef0502040d2a238ad22487c0",slug:"forecasting-in-mathematics-recent-advances-new-perspectives-and-applications",bookSignature:"Abdo Abou Jaoude",coverURL:"https://cdn.intechopen.com/books/images_new/10062.jpg",editedByType:"Edited by",editors:[{id:"248271",title:"Dr.",name:"Abdo",middleName:null,surname:"Abou Jaoude",slug:"abdo-abou-jaoude",fullName:"Abdo Abou Jaoude"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9043",title:"Parenting",subtitle:"Studies by an Ecocultural and Transactional Perspective",isOpenForSubmission:!1,hash:"6d21066c7438e459e4c6fb13217a5c8c",slug:"parenting-studies-by-an-ecocultural-and-transactional-perspective",bookSignature:"Loredana Benedetto and Massimo Ingrassia",coverURL:"https://cdn.intechopen.com/books/images_new/9043.jpg",editedByType:"Edited by",editors:[{id:"193200",title:"Prof.",name:"Loredana",middleName:null,surname:"Benedetto",slug:"loredana-benedetto",fullName:"Loredana Benedetto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10075",title:"Nonlinear Optics",subtitle:"From Solitons to Similaritons",isOpenForSubmission:!1,hash:"b034b2a060292c8511359aec0db1002c",slug:"nonlinear-optics-from-solitons-to-similaritons",bookSignature:"İlkay Bakırtaş and Nalan Antar",coverURL:"https://cdn.intechopen.com/books/images_new/10075.jpg",editedByType:"Edited by",editors:[{id:"186388",title:"Prof.",name:"İlkay",middleName:null,surname:"Bakırtaş",slug:"ilkay-bakirtas",fullName:"İlkay Bakırtaş"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10116",title:"Nano- and Microencapsulation",subtitle:"Techniques and Applications",isOpenForSubmission:!1,hash:"8d92c5999718734b36a0cc3a6af7c7f6",slug:"nano-and-microencapsulation-techniques-and-applications",bookSignature:"Nedal Abu-Thabit",coverURL:"https://cdn.intechopen.com/books/images_new/10116.jpg",editedByType:"Edited by",editors:[{id:"308436",title:"Associate Prof.",name:"Nedal",middleName:null,surname:"Abu-Thabit",slug:"nedal-abu-thabit",fullName:"Nedal Abu-Thabit"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9881",title:"Perovskite and Piezoelectric Materials",subtitle:null,isOpenForSubmission:!1,hash:"8fa0e0f48567bbc50fbb3bfdde6f9a0b",slug:"perovskite-and-piezoelectric-materials",bookSignature:"Someshwar Pola, Neeraj Panwar and Indrani Coondoo",coverURL:"https://cdn.intechopen.com/books/images_new/9881.jpg",editedByType:"Edited by",editors:[{id:"177037",title:"Dr.",name:"Someshwar",middleName:null,surname:"Pola",slug:"someshwar-pola",fullName:"Someshwar Pola"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9394",title:"Genotoxicity and Mutagenicity",subtitle:"Mechanisms and Test Methods",isOpenForSubmission:!1,hash:"9ee7e597358dbbfb5e33d0beb76e6fff",slug:"genotoxicity-and-mutagenicity-mechanisms-and-test-methods",bookSignature:"Sonia Soloneski and Marcelo L. Larramendy",coverURL:"https://cdn.intechopen.com/books/images_new/9394.jpg",editedByType:"Edited by",editors:[{id:"14863",title:"Dr.",name:"Sonia",middleName:null,surname:"Soloneski",slug:"sonia-soloneski",fullName:"Sonia Soloneski"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"265",title:"Education",slug:"social-sciences-education",parent:{title:"Social Sciences",slug:"social-sciences"},numberOfBooks:23,numberOfAuthorsAndEditors:390,numberOfWosCitations:46,numberOfCrossrefCitations:138,numberOfDimensionsCitations:221,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"social-sciences-education",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editedByType:"Edited by",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8283",title:"Innovations in Higher Education",subtitle:"Cases on Transforming and Advancing Practice",isOpenForSubmission:!1,hash:"9c8b8a6fe8578fbf2398932ce8c1b717",slug:"innovations-in-higher-education-cases-on-transforming-and-advancing-practice",bookSignature:"Dominique Parrish and Joanne Joyce-McCoach",coverURL:"https://cdn.intechopen.com/books/images_new/8283.jpg",editedByType:"Edited by",editors:[{id:"197795",title:"Associate Prof.",name:"Dominique",middleName:null,surname:"Parrish",slug:"dominique-parrish",fullName:"Dominique Parrish"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7906",title:"The Essence of Academic Performance",subtitle:null,isOpenForSubmission:!1,hash:"69e39465b02c12b562c004ed8d591710",slug:"the-essence-of-academic-performance",bookSignature:"Bernard Nchindila and Trudy Corrigan",coverURL:"https://cdn.intechopen.com/books/images_new/7906.jpg",editedByType:"Edited by",editors:[{id:"196855",title:"Prof.",name:"Bernard",middleName:"Mwansa",surname:"Nchindila",slug:"bernard-nchindila",fullName:"Bernard Nchindila"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7819",title:"Education Systems Around the World",subtitle:null,isOpenForSubmission:!1,hash:"c3d5598e631502952f75b2181873f6ea",slug:"education-systems-around-the-world",bookSignature:"Gilson Porto Jr.",coverURL:"https://cdn.intechopen.com/books/images_new/7819.jpg",editedByType:"Edited by",editors:[{id:"279817",title:"Dr.",name:"Gilson",middleName:null,surname:"Porto",slug:"gilson-porto",fullName:"Gilson Porto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7601",title:"Game Design and Intelligent Interaction",subtitle:null,isOpenForSubmission:!1,hash:"aef7c5d14fb716604538b9f7e1a3f2ef",slug:"game-design-and-intelligent-interaction",bookSignature:"Ioannis Deliyannis",coverURL:"https://cdn.intechopen.com/books/images_new/7601.jpg",editedByType:"Edited by",editors:[{id:"103622",title:"Dr.",name:"Ioannis",middleName:null,surname:"Deliyannis",slug:"ioannis-deliyannis",fullName:"Ioannis Deliyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8495",title:"Educational Leadership",subtitle:null,isOpenForSubmission:!1,hash:"387155f6ce16da4065319ac18ef9bf1f",slug:"educational-leadership",bookSignature:"Hülya Şenol",coverURL:"https://cdn.intechopen.com/books/images_new/8495.jpg",editedByType:"Edited by",editors:[{id:"240203",title:"Dr.",name:"Hülya",middleName:null,surname:"Şenol",slug:"hulya-senol",fullName:"Hülya Şenol"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8039",title:"Theorizing STEM Education in the 21st Century",subtitle:null,isOpenForSubmission:!1,hash:"0c99d528dbcc6ed5e8a26f96b36c812d",slug:"theorizing-stem-education-in-the-21st-century",bookSignature:"Kehdinga George Fomunyam",coverURL:"https://cdn.intechopen.com/books/images_new/8039.jpg",editedByType:"Edited by",editors:[{id:"267912",title:"Dr.",name:"Kehdinga George",middleName:null,surname:"Fomunyam",slug:"kehdinga-george-fomunyam",fullName:"Kehdinga George Fomunyam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9040",title:"Pedagogy in Basic and Higher Education",subtitle:"Current Developments and Challenges",isOpenForSubmission:!1,hash:"3ef45143bf2a8d798f0e423e098afe6c",slug:"pedagogy-in-basic-and-higher-education-current-developments-and-challenges",bookSignature:"Kirsi Tirri and Auli Toom",coverURL:"https://cdn.intechopen.com/books/images_new/9040.jpg",editedByType:"Edited by",editors:[{id:"234399",title:"Prof.",name:"Kirsi",middleName:null,surname:"Tirri",slug:"kirsi-tirri",fullName:"Kirsi Tirri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8645",title:"Contemporary Topics in Graduate Medical Education",subtitle:null,isOpenForSubmission:!1,hash:"76d224ba3c158c43fda8141a61ababd6",slug:"contemporary-topics-in-graduate-medical-education",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, James P. Orlando and Thomas J. Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/8645.jpg",editedByType:"Edited by",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6929",title:"Active Learning",subtitle:"Beyond the Future",isOpenForSubmission:!1,hash:"fe54807c3ff7c1b500127e814988f5e2",slug:"active-learning-beyond-the-future",bookSignature:"Sílvio Manuel Brito",coverURL:"https://cdn.intechopen.com/books/images_new/6929.jpg",editedByType:"Edited by",editors:[{id:"170935",title:"Ph.D.",name:"Sílvio Manuel",middleName:"Da Rocha",surname:"Brito",slug:"silvio-manuel-brito",fullName:"Sílvio Manuel Brito"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7804",title:"Teacher Education in the 21st Century",subtitle:null,isOpenForSubmission:!1,hash:"1722e45e6ebd731426bc0e4ac5c6eee2",slug:"teacher-education-in-the-21st-century",bookSignature:"Reginald Botshabeng Monyai",coverURL:"https://cdn.intechopen.com/books/images_new/7804.jpg",editedByType:"Edited by",editors:[{id:"210249",title:"Dr.",name:"Reginald",middleName:"Botshabeng",surname:"Monyai",slug:"reginald-monyai",fullName:"Reginald Monyai"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6936",title:"Early Childhood Education",subtitle:null,isOpenForSubmission:!1,hash:"f4092f476f58833b460010a63f5397dc",slug:"early-childhood-education",bookSignature:"Donna Farland-Smith",coverURL:"https://cdn.intechopen.com/books/images_new/6936.jpg",editedByType:"Edited by",editors:[{id:"197003",title:"Dr.",name:"Donna",middleName:null,surname:"Farland-Smith",slug:"donna-farland-smith",fullName:"Donna Farland-Smith"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:23,mostCitedChapters:[{id:"59705",doi:"10.5772/intechopen.74943",title:"Augmented Reality Trends in Education between 2016 and 2017 Years",slug:"augmented-reality-trends-in-education-between-2016-and-2017-years",totalDownloads:1563,totalCrossrefCites:13,totalDimensionsCites:15,book:{slug:"state-of-the-art-virtual-reality-and-augmented-reality-knowhow",title:"State of the Art Virtual Reality and Augmented Reality Knowhow",fullTitle:"State of the Art Virtual Reality and Augmented Reality Knowhow"},signatures:"Rabia M. Yilmaz",authors:[{id:"225838",title:"Dr.",name:"Rabia",middleName:null,surname:"Yilmaz",slug:"rabia-yilmaz",fullName:"Rabia Yilmaz"}]},{id:"32519",doi:"10.5772/33745",title:"Self-Regulated Learning Activities: Supporting Success in Online Courses",slug:"self-regulated-learning-activities-supporting-success-in-online-courses-",totalDownloads:2264,totalCrossrefCites:1,totalDimensionsCites:10,book:{slug:"international-perspectives-of-distance-learning-in-higher-education",title:"International Perspectives of Distance Learning in Higher Education",fullTitle:"International Perspectives of Distance Learning in Higher Education"},signatures:"Maureen Snow Andrade",authors:[{id:"96902",title:"Dr.",name:"Maureen",middleName:null,surname:"Snow Andrade",slug:"maureen-snow-andrade",fullName:"Maureen Snow Andrade"}]},{id:"32516",doi:"10.5772/32879",title:"Open and Distance Learning in Dual Mode Universities: A Treasure Unexploited",slug:"open-and-distance-learning-in-dual-mode-universities-a-treasure-unexploited",totalDownloads:4929,totalCrossrefCites:4,totalDimensionsCites:9,book:{slug:"international-perspectives-of-distance-learning-in-higher-education",title:"International Perspectives of Distance Learning in Higher Education",fullTitle:"International Perspectives of Distance Learning in Higher Education"},signatures:"Paul Birevu Muyinda",authors:[{id:"93065",title:"Dr.",name:"Paul",middleName:null,surname:"Birevu Muyinda",slug:"paul-birevu-muyinda",fullName:"Paul Birevu Muyinda"}]}],mostDownloadedChaptersLast30Days:[{id:"58060",title:"Pedagogy of the Twenty-First Century: Innovative Teaching Methods",slug:"pedagogy-of-the-twenty-first-century-innovative-teaching-methods",totalDownloads:6680,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"new-pedagogical-challenges-in-the-21st-century-contributions-of-research-in-education",title:"New Pedagogical Challenges in the 21st Century",fullTitle:"New Pedagogical Challenges in the 21st Century - Contributions of Research in Education"},signatures:"Aigerim Mynbayeva, Zukhra Sadvakassova and Bakhytkul\nAkshalova",authors:[{id:"201997",title:"Dr.",name:"Aigerim",middleName:null,surname:"Mynbayeva",slug:"aigerim-mynbayeva",fullName:"Aigerim Mynbayeva"},{id:"209208",title:"Dr.",name:"Zukhra",middleName:null,surname:"Sadvakassova",slug:"zukhra-sadvakassova",fullName:"Zukhra Sadvakassova"},{id:"209210",title:"Dr.",name:"Bakhytkul",middleName:null,surname:"Akshalova",slug:"bakhytkul-akshalova",fullName:"Bakhytkul Akshalova"}]},{id:"61746",title:"Facilitation of Teachers’ Professional Development through Principals’ Instructional Supervision and Teachers’ Knowledge- Management Behaviors",slug:"facilitation-of-teachers-professional-development-through-principals-instructional-supervision-and-t",totalDownloads:2042,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"contemporary-pedagogies-in-teacher-education-and-development",title:"Contemporary Pedagogies in Teacher Education and Development",fullTitle:"Contemporary Pedagogies in Teacher Education and Development"},signatures:"Chien-Chin Chen",authors:[{id:"232569",title:"Ph.D.",name:"Chien Chih",middleName:null,surname:"Chen",slug:"chien-chih-chen",fullName:"Chien Chih Chen"}]},{id:"59408",title:"Enhancing BIM Methodology with VR Technology",slug:"enhancing-bim-methodology-with-vr-technology",totalDownloads:2492,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"state-of-the-art-virtual-reality-and-augmented-reality-knowhow",title:"State of the Art Virtual Reality and Augmented Reality Knowhow",fullTitle:"State of the Art Virtual Reality and Augmented Reality Knowhow"},signatures:"Alcínia Zita Sampaio",authors:[{id:"13640",title:"Prof.",name:"Alcínia Zita",middleName:"Almeida",surname:"Sampaio",slug:"alcinia-zita-sampaio",fullName:"Alcínia Zita Sampaio"}]},{id:"59705",title:"Augmented Reality Trends in Education between 2016 and 2017 Years",slug:"augmented-reality-trends-in-education-between-2016-and-2017-years",totalDownloads:1563,totalCrossrefCites:13,totalDimensionsCites:15,book:{slug:"state-of-the-art-virtual-reality-and-augmented-reality-knowhow",title:"State of the Art Virtual Reality and Augmented Reality Knowhow",fullTitle:"State of the Art Virtual Reality and Augmented Reality Knowhow"},signatures:"Rabia M. Yilmaz",authors:[{id:"225838",title:"Dr.",name:"Rabia",middleName:null,surname:"Yilmaz",slug:"rabia-yilmaz",fullName:"Rabia Yilmaz"}]},{id:"63925",title:"Curriculum Development: Foundations and Modern Advances in Graduate Medical Education",slug:"curriculum-development-foundations-and-modern-advances-in-graduate-medical-education",totalDownloads:1573,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"contemporary-topics-in-graduate-medical-education",title:"Contemporary Topics in Graduate Medical Education",fullTitle:"Contemporary Topics in Graduate Medical Education"},signatures:"Simiao Li-Sauerwine and Andrew King",authors:null},{id:"59816",title:"Augmented Reality and Virtual Reality: Initial Successes in Diagnostic Radiology",slug:"augmented-reality-and-virtual-reality-initial-successes-in-diagnostic-radiology",totalDownloads:1166,totalCrossrefCites:2,totalDimensionsCites:5,book:{slug:"state-of-the-art-virtual-reality-and-augmented-reality-knowhow",title:"State of the Art Virtual Reality and Augmented Reality Knowhow",fullTitle:"State of the Art Virtual Reality and Augmented Reality Knowhow"},signatures:"David B. Douglas, Demetri Venets, Cliff Wilke, David Gibson, Lance\nLiotta, Emanuel Petricoin, Buddy Beck and Robert Douglas",authors:[{id:"86918",title:"Dr.",name:"Emanuel",middleName:null,surname:"Petricoin",slug:"emanuel-petricoin",fullName:"Emanuel Petricoin"},{id:"122098",title:"Dr.",name:"Lance",middleName:null,surname:"Liotta",slug:"lance-liotta",fullName:"Lance Liotta"},{id:"225961",title:"Dr.",name:"David",middleName:null,surname:"Douglas",slug:"david-douglas",fullName:"David Douglas"},{id:"240843",title:"Dr.",name:"Demetri",middleName:null,surname:"Venets",slug:"demetri-venets",fullName:"Demetri Venets"},{id:"240844",title:"MSc.",name:"Cliff",middleName:null,surname:"Wilke",slug:"cliff-wilke",fullName:"Cliff Wilke"},{id:"240846",title:"MSc.",name:"David",middleName:null,surname:"Gibson",slug:"david-gibson",fullName:"David Gibson"},{id:"240847",title:"Mr.",name:"Buddy",middleName:null,surname:"Beck",slug:"buddy-beck",fullName:"Buddy Beck"},{id:"240848",title:"Dr.",name:"Robert",middleName:null,surname:"Douglas",slug:"robert-douglas",fullName:"Robert Douglas"}]},{id:"61592",title:"Educating Professional Teachers in Finland through the Continuous Improvement of Teacher Education Programmes",slug:"educating-professional-teachers-in-finland-through-the-continuous-improvement-of-teacher-education-p",totalDownloads:1103,totalCrossrefCites:4,totalDimensionsCites:5,book:{slug:"contemporary-pedagogies-in-teacher-education-and-development",title:"Contemporary Pedagogies in Teacher Education and Development",fullTitle:"Contemporary Pedagogies in Teacher Education and Development"},signatures:"Jari Lavonen",authors:[{id:"235077",title:"Prof.",name:"Jari",middleName:null,surname:"Lavonen",slug:"jari-lavonen",fullName:"Jari Lavonen"}]},{id:"65030",title:"Lack of Qualified Teachers: A Global Challenge for Future Knowledge Development",slug:"lack-of-qualified-teachers-a-global-challenge-for-future-knowledge-development",totalDownloads:1229,totalCrossrefCites:2,totalDimensionsCites:3,book:{slug:"teacher-education-in-the-21st-century",title:"Teacher Education in the 21st Century",fullTitle:"Teacher Education in the 21st Century"},signatures:"Mona Holmqvist",authors:[{id:"275455",title:"Prof.",name:"Mona",middleName:null,surname:"Holmqvist",slug:"mona-holmqvist",fullName:"Mona Holmqvist"}]},{id:"60297",title:"Teachers’ Knowledge of Curriculum Integration: A Current Challenge for Finnish Subject Teachers",slug:"teachers-knowledge-of-curriculum-integration-a-current-challenge-for-finnish-subject-teachers",totalDownloads:1127,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"contemporary-pedagogies-in-teacher-education-and-development",title:"Contemporary Pedagogies in Teacher Education and Development",fullTitle:"Contemporary Pedagogies in Teacher Education and Development"},signatures:"Mikko A. Niemelä and Kirsi Tirri",authors:[{id:"234399",title:"Prof.",name:"Kirsi",middleName:null,surname:"Tirri",slug:"kirsi-tirri",fullName:"Kirsi Tirri"},{id:"242136",title:"Ph.D. Student",name:"Mikko",middleName:null,surname:"Niemelä",slug:"mikko-niemela",fullName:"Mikko Niemelä"}]},{id:"69579",title:"Developing and Evaluating Educational Programs",slug:"developing-and-evaluating-educational-programs",totalDownloads:418,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"the-essence-of-academic-performance",title:"The Essence of Academic Performance",fullTitle:"The Essence of Academic Performance"},signatures:"B. Charles Tatum",authors:[{id:"305050",title:"Dr.",name:"Charles",middleName:null,surname:"Tatum",slug:"charles-tatum",fullName:"Charles Tatum"}]}],onlineFirstChaptersFilter:{topicSlug:"social-sciences-education",limit:3,offset:0},onlineFirstChaptersCollection:[{id:"74760",title:"Using Ideation Grids to Power Collaborative Creativity in Face-to-Face and Remote Innovation Sessions",slug:"using-ideation-grids-to-power-collaborative-creativity-in-face-to-face-and-remote-innovation-session",totalDownloads:26,totalDimensionsCites:0,doi:"10.5772/intechopen.93850",book:{title:"Creativity - A Force to Innovation"},signatures:"John Knight, Elliot Ross and Dan Fitton"},{id:"73433",title:"Assessment of Creativity: Theories and Methods",slug:"assessment-of-creativity-theories-and-methods",totalDownloads:81,totalDimensionsCites:0,doi:"10.5772/intechopen.93971",book:{title:"Creativity - A Force to Innovation"},signatures:"Esra Kanlı"},{id:"73781",title:"The Light Penetrates Silence: Kolok Dance Study in Bengkala Village, Buleleng, Bali",slug:"the-light-penetrates-silence-kolok-dance-study-in-bengkala-village-buleleng-bali",totalDownloads:63,totalDimensionsCites:0,doi:"10.5772/intechopen.94397",book:{title:"Creativity - A Force to Innovation"},signatures:"Ida Ayu Trisnawati"}],onlineFirstChaptersTotal:10},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/75332/chikumbusko-chiziwa-kaonga",hash:"",query:{},params:{id:"75332",slug:"chikumbusko-chiziwa-kaonga"},fullPath:"/profiles/75332/chikumbusko-chiziwa-kaonga",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()